Skip to Content
MoleculesMolecules
  • Review
  • Open Access

21 November 2026

29 Pages

Health Risks of Melatonin-Containing Food Supplements

and
German Federal Institute for Risk Assessment, Department Food and Feed Safety in the Food Chain, 10589 Berlin, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules2026, 31(23), 4240;https://doi.org/10.3390/molecules31234240 
(registering DOI)
This article belongs to the Special Issue Natural and Synthetic Bioactive Compounds in Food—Risks and Benefits

Abstract

Melatonin is a hormone naturally produced by the body that is involved in regulating the sleep–wake cycle, among other functions. As an active ingredient in prescription drugs, it is authorised for the temporary treatment of sleep disorders in certain patient groups in Europe. For several years, food supplements containing this bioactive compound have also been marketed in many countries. This narrative review examines the potential health risks associated with the use of melatonin-containing food supplements, considering the pharmacokinetic properties of exogenous melatonin, interindividual variability, regulatory aspects, product characteristics and findings on potential adverse health effects in different population groups, including healthy adults, pregnant and breastfeeding women, and children. The available evidence indicates considerable interindividual variability in melatonin pharmacokinetics, with supraphysiological plasma concentrations potentially occurring even after low oral doses. Acute adverse effects in healthy adults are generally mild, but evidence regarding long-term safety remains insufficient. Findings on endocrine, reproductive, cardiovascular and metabolic effects are inconsistent or remain inconclusive. Data on safety in children, adolescents, pregnancy and breastfeeding are particularly limited. Overall, given the uncertainties regarding long-term safety and the potential for prolonged systemic exposure in certain individuals, uncontrolled and prolonged use of melatonin-containing food supplements should be approached with caution, particularly in vulnerable population groups.

1. Introduction

Melatonin is a naturally occurring hormone that regulates numerous processes that follow a circadian rhythm, in particular the sleep–wake cycle, as well as other physiological processes, such as the regulation of body temperature, blood pressure, glucose homeostasis, and the secretion of other endogenous hormones [1,2]. These effects can be mediated both by endogenously produced melatonin and by exogenously administered melatonin [2,3].
This review focuses on the variability of the pharmacokinetic properties of melatonin, the regulatory framework for melatonin-containing food supplements (FSs), and the potential health risks that may result from their consumption. The aim is to evaluate the health risks associated with melatonin as an ingredient in FSs, with the reference group being the general population (i.e., healthy individuals).
A comprehensive literature search was conducted for this narrative review, focusing on human studies. The search covered all publications with the term ‘melatonin’ in the title and/or abstract, as well as a combination of relevant keywords. The search covered all publications available up to October 2026. The MEDLINE database (via the PubMed search interface) was used, and the search strategy covered the main aspects addressed in this review, including the pharmacokinetics, product characteristics, patterns of use, and safety of melatonin-containing products in children and adults. Relevant publications were identified and selected based on their scientific relevance and contribution to understanding the topic, as well as their relevance to the main objectives of this review. Additionally, relevant regulatory documents and assessments from regulatory authorities (e.g., the European Union (EU), European Food Safety Authority (EFSA) and European Medicines Agency (EMA)) were reviewed to identify information on melatonin-containing products.

2. Physiological Function of Melatonin in the Human Body

Melatonin is a naturally occurring hormone that is formed and released primarily in the epiphysis (pineal gland) as well as in certain cells of the digestive tract and the retina. Melatonin synthesis follows a multistage process involving L-tryptophan and serotonin. Light stimuli received via the retina inhibit its biosynthesis; hence, endogenous melatonin concentration in the blood is subject to a marked day–night rhythm [1].
Melatonin is associated with the regulation of the complex circadian rhythm and the synchronisation of the body’s internal clock with the sleep–wake cycle. Melatonin is likewise associated with a sleep-promoting effect and an increase in drowsiness, as it acts on the MT1 and MT2 receptors in the central nervous system. Melatonin receptors are also present in various other bodily organs, tissues and cells, such as the retina, the cardiovascular system, the gastrointestinal tract, blood vessels and immune cells [4].
In addition to its key role in regulating sleep, melatonin is also involved in numerous other physiological processes following a circadian rhythm, such as regulating body temperature and releasing other hormones in the body. Finally, there are indications that melatonin has immunomodulating properties and is involved in regulating blood pressure and in glucose homeostasis [2,3,5,6].

3. Kinetics of Melatonin in the Human Body

3.1. Production and Kinetics of Endogenous Melatonin

After synthesis, melatonin is released directly into the blood without being stored in the epiphysis [2]. Melatonin production and secretion in the epiphysis are inhibited by light, with darkness lifting this inhibition. With the onset of dusk, physiological melatonin secretion increases (known as “dim light melatonin onset” or DLMO, a circadian phase marker), with plasma concentrations reaching their peak at around 2–4 am, after which they decrease steadily until the morning. Overall, endogenous melatonin levels are regulated in the picogram range. Nocturnal endogenous melatonin plasma concentrations are between 60 and 120 pg/mL, whereas during the day, the maximum concentration, if detectable at all, is 10–20 pg/mL [2].
Although there is significant variation in measurable plasma melatonin concentrations between individuals, intraindividual levels fluctuate only slightly from day to day, indicating a robust circadian rhythm overall [2]. The plasma melatonin concentration profile is also impacted by individual chronotype. For example, the nocturnal melatonin peak in people with an evening chronotype occurs later than in people with an early chronotype [7].
The circadian rhythm develops during the first year of life, with very low melatonin levels present in the first weeks to months after birth [8,9]. In particular, no endogenous melatonin production is detectable in the first days of life in premature babies, as measured by melatonin concentration in blood plasma [10,11]. Children between four and seven years of age have the highest nocturnal plasma melatonin concentrations, while concentrations fall continuously, in particular from before the start of puberty and with increasing age [3,12,13]. In children and young adults with specific abnormalities of neurological development, for example, on the autism spectrum, nocturnal plasma melatonin concentrations are frequently lower than in people not affected in the same way [14,15].
Overall, the kinetics of endogenous melatonin in the human body are subject to interindividual variability in terms of the timing of the increase in endogenous melatonin secretion (DLMO) throughout the day and in terms of plasma melatonin levels reached. The factors underlying this variability include the individual chronotype, age and stage of development.

3.2. Kinetics of Exogenous Melatonin and Variability Factors

The available data on the kinetics of exogenous melatonin in humans come either from reports of the European Medicines Agency (EMA) on a specific authorised medicinal product with a well-characterised melatonin formulation or from studies using different, often less well-characterised, melatonin formulations with variable dosages (see Section 4).
Exogenous, orally administered melatonin is almost completely absorbed via the gastrointestinal tract, although absorption may be decreased in the elderly [16]. However, due to a marked first-pass effect in the liver, it exhibits highly variable systemic exposure. Therefore, the oral bioavailability, which is rarely reported in studies, is estimated to be around 15%, with values ranging from approximately 3% to 56%, also depending on the formulation of the melatonin preparations [3,17,18,19].
Exogenous melatonin leads to a dose-dependent increase in plasma levels. Even an oral dose of about 0.5 mg can lead to supraphysiological melatonin plasma levels [20,21]—concentrations that exceed the physiological nocturnal peak of endogenous melatonin—and oral intake of melatonin in doses of 1 to 5 mg leads to plasma levels that are 10 to 100 times higher than physiological levels [3]. Administration of higher doses or prolonged-release formulations can maintain those elevated plasma concentrations for several hours, potentially extending into the following day in some individuals [3,19,22,23]. The peak plasma melatonin concentration is reached between 15 and 90 min after administration of immediate-release formulations and after more than 80 min for prolonged-release formulations, also depending on the specific galenic formulation [17,19]. It should be noted that formulation-related factors, including specific release characteristics, route of administration and composition of the formulation, affect the pharmacokinetic properties of exogenous melatonin. Studies directly comparing different melatonin formulations with the same dosage have shown that sustained-release formulations produce lower and later peak plasma levels than immediate-release formulations and prolong the duration of elevated plasma melatonin levels [24,25,26]. Sublingual administration (spray or dissolving tablet) may bypass the first-pass effect, potentially leading to higher melatonin bioavailability [19]. One small study found that administering an immediate-release sublingual spray of 1 mg of melatonin led to an earlier and higher melatonin plasma peak, as well as a higher dose-adjusted bioavailability, compared to an oral prolonged-release tablet of 1.9 mg of melatonin [27]. However, as not only the route of administration but also the galenic/release form differed, no clear conclusion can be drawn from this study about whether sublingual application results in better bioavailability. Additionally, food intake can influence the concentration–time profile of melatonin after oral administration, resulting in higher or lower peak plasma melatonin levels depending on the specific formulation of melatonin administered [16,28,29,30].
Melatonin is primarily bound to albumin and distributed via the bloodstream to various tissues in the body [31]. It can also cross the blood–brain barrier and the placenta and enter breast milk, thereby reaching the foetus or infant [5]. Melatonin is thought to be metabolised predominantly in the liver by cytochrome P450 (CYP) isoenzymes, in particular CYP1A2, with contributions from CYP1A1 and possibly CYP2C19, yielding 6-hydroxymelatonin, which is subsequently converted mainly to 6-sulfatoxymelatonin excreted in urine [18,32]. Immediate-release formulations of orally administered melatonin have been reported to have a plasma half-life of approximately 45 min, whereas specific prolonged-release formulations are reported to have a terminal half-life of about 3.5–4 h [25], resulting in a more prolonged plasma concentration–time profile [17,23]. In older adults, higher doses of melatonin (i.e., 4–5 mg) in prolonged-release formulations caused elevated melatonin levels (>50 pg/mL) up to 10 h after administration [22]. Data also reveal a modification of the endogenous melatonin rhythm following exogenous melatonin administration (‘phase shift’), with a dose-dependent premature increase in endogenous melatonin release the day after evening or night administration [19,20,33,34,35].
The kinetics of exogenously administered melatonin, in particular with respect to peak plasma concentrations and elimination, vary considerably between individuals, depending, for example, on age, gender and genetic factors. The activity of the most relevant melatonin-metabolising enzyme (CYP1A2) has been found to display significant interindividual variability, influenced by both genetic and non-genetic factors [36]. However, the magnitude of this variability reported in the literature varies depending on the experimental approach. Differences have been observed between in vitro assessments of enzyme expression or activity and in vivo phenotyping studies using probe substrates such as caffeine. In vivo phenotyping studies commonly report interindividual differences in CYP1A2 activity in the range of approximately 5- to 15-fold, although wider ranges have also been reported, depending on the population studied and the methodology used [37,38,39]. In this context, there are indications of gender-specific differences, with higher maximum plasma levels reported in women compared to men, as well as age-specific differences in metabolic and elimination rates for melatonin, with a lower capacity reported in older individuals and infants [19,23,30,40,41]. As already described above, older adults frequently exhibit higher, more prolonged and, overall, a wider range of variation in plasma melatonin concentrations following the same oral dose than younger adult individuals [21,23,40,42,43,44]. There are considerable differences in metabolic capacity for melatonin between children at an early stage of development and older children and adults. More generally, owing to their body composition and development-related growth and maturation processes, children may differ from adults in specific aspects of the pharmacokinetics (absorption, distribution, metabolism, elimination) and/or pharmacodynamics of exogenous substances. In early development, the capacity to metabolise melatonin is virtually absent or very limited. In newborns, the activity of CYP1A2 is reported to be negligible; a markedly prolonged and inter-individually variable elimination half-life and reduced clearance of melatonin have been reported in premature infants [45,46,47]. Investigations into the expression of the melatonin-metabolising CYP1A2 enzyme in the human liver showed markedly lower protein expression and enzyme-associated activity in babies aged three to twelve months compared with adults (approximately 20–25% of adult values), while values in infants aged 1 year were roughly 50% of adult values [41,46]. Hence, a longer elimination half-life may also be suspected in later childhood; however, studies on the pharmacokinetic properties of melatonin in healthy children are lacking [48].
In addition, genetic factors, such as specific polymorphisms in the CYP1A2 gene, may also influence the metabolic capacity for melatonin, including hepatic first-pass metabolism as well as systemic elimination, contributing to interindividual variability. In individuals with a “slow metaboliser” phenotype, this may result in prolonged exposure to elevated supraphysiological melatonin plasma levels [49,50].
When interpreting the available pharmacokinetic data, it is also important to consider the heterogeneity of the analytical methods used to quantify melatonin in biological samples. Studies investigating the pharmacokinetics of exogenous melatonin over several decades have employed different methods, predominantly radioimmunoassays (RIAs), but also enzyme-linked immunosorbent assays (ELISAs), gas chromatography–mass spectrometry (GC-MS) and, more recently, liquid chromatography–tandem mass spectrometry (LC-MS/MS). These methods differ in their analytical sensitivity, specificity, accuracy and susceptibility to cross-reactivity, as well as in the extent of their validation [51,52,53,54]. Direct comparisons have demonstrated relevant discrepancies between specific immunoassays and LC-MS/MS methods, despite generally good correlations [55,56,57,58]. Depending on the specific assay and sample preparation, immunoassays may be affected by cross-reactivity with structurally related compounds and matrix-related interference, potentially resulting in overestimation or unreliable quantification, particularly at low melatonin concentrations [51,52]. Although LC-MS/MS generally offers higher analytical selectivity, its performance also depends on appropriate method validation, sample preparation and control of matrix effects. Consequently, differences in analytical methods and their validation may affect the comparability of reported melatonin concentrations and the estimation of pharmacokinetic parameters, particularly at low concentrations during the terminal elimination phase. However, their contribution to the reported interindividual pharmacokinetic variability cannot currently be quantified. In addition, sampling conditions, including ambient light, body posture and sampling times, may influence measured melatonin concentrations, highlighting the need for standardised analytical and sampling protocols [53].
Taken together, oral administration of melatonin results in substantial interindividual variability in systemic exposure. This variability is likely attributable to a combination of physiological, metabolic, genetic and formulation-related factors. However, differences in bioanalytical methods and their validation across studies may additionally affect the comparability of reported melatonin concentrations and pharmacokinetic parameters and should therefore be considered when interpreting the available evidence. Supraphysiological plasma concentrations may occur even at doses below 0.5 mg of melatonin in some individuals, with potentially prolonged supraphysiological levels in certain subpopulations, such as the elderly, infants or genetically slow metabolisers. Reduced metabolic capacity for melatonin can result in prolonged systemic exposure and potential next-day carryover, with elevated plasma concentrations remaining the following day. It is unclear whether this may result in pharmacokinetic accumulation following repeated once-daily administration, particularly in individuals with markedly reduced metabolic capacity who use higher doses over prolonged periods. Furthermore, the administration of exogenous melatonin influences the endogenous melatonin rhythm. Bioavailability also varies significantly depending on the dosage and the specific formulation of administered melatonin, as well as other exogenous factors such as meal intake, smoking and the intake of other (pharmacological) substances (see Section 5.1.4). There is a lack of high-quality studies that directly compare the different forms of active substance release with regard to pharmacokinetic properties and the resulting melatonin exposure of melatonin-containing products and an overall lack of data on the pharmacokinetic properties of exogenous melatonin in children.

4. Melatonin in Medicinal Products vs. Food Supplements

4.1. Melatonin in Medicinal Products

Due to its role in regulating the sleep–wake rhythm, the EMA has authorised melatonin as a pharmaceutical substance in certain prescription-only medicinal products for treating sleep disorders in specific patient groups. In Europe, one authorised indication is the short-term treatment of primary insomnia characterised by poor quality of sleep in people aged 55 years or older. Specific prolonged-release formulations containing 2 mg of melatonin are authorised for once-daily oral use, with treatment generally limited to a maximum of 13 weeks [16,32,59]. A further prolonged-release melatonin-containing medicinal product is authorised for the treatment of insomnia in children and adolescents aged 2–18 years with autism spectrum disorder (ASD) and/or neurogenetic disorders associated with abnormal melatonin production and/or nocturnal awakenings, as well as in children and adolescents aged 6 to 17 years with attention-deficit hyperactivity disorder (ADHD), where sleep hygiene measures have been insufficient in both cases [16]. In addition to these authorised uses, a doctor may prescribe a medicinal product containing melatonin outside its authorised use if they consider it medically appropriate, having assessed the potential benefits and risks on a case-by-case basis.
Studies from northern European countries indicate a continuous increase in the use of melatonin in medicinal products among children and young adults and a high proportion of relatively young children being prescribed melatonin over long periods [60,61,62,63]. Increasing prescription rates of melatonin have also been reported among children in France and across the whole population in the UK, with the highest primary care prescription rates among children and older people [64,65].

4.2. Melatonin in Food Supplements

4.2.1. Regulatory Status

Prescription-only medicinal products containing melatonin are authorised for specific indications, patient populations and, in most cases, defined treatment durations. Their development and authorisation involve the assessment of quality, efficacy and safety, including a risk–benefit assessment for the intended use. In addition, treatment with medicinal products is generally accompanied by an individual medical benefit–risk assessment as well as regular medical monitoring of the treatment progress.
In contrast, food supplements (FSs) are legally defined as foods in the European Union (EU) and not as medicinal products [66]. They are intended to supplement the normal diet (of healthy individuals) and are concentrated sources of nutrients or other substances with a nutritional or physiological effect, either alone or in combination. They are marketed in dosed form, such as capsules, tablets, sachets of powder or ampoules of liquids, designed to be taken in small measured quantities [67]. Under food law, food that is not safe must not be placed on the market [66]. However, unlike medicinal products, FSs are not reviewed or approved by regulatory authorities before they are placed on the market; hence, efficacy and safety for a specific indication or population group are generally not assessed before marketing. The manufacturer is responsible for ensuring the safety of the food (supplement) [67]. Furthermore, there are hardly any EU-wide, legally established maximum limits for ingredients in FSs. Table 1 summarises the key regulatory differences between food supplements and medicinal products in the EU and Germany.
Table 1. Regulatory differences between food supplements and medicinal products in the EU and Germany.
Although there are harmonised legal frameworks, the classification of certain substances—also defined as “other substances”—as food or drugs is not entirely uniform, even at the European level, and is sometimes interpreted differently by various Member States. Consequently, a substance that is lawfully marketed as a dietary supplement in one European Member State may be subject to national pharmaceutical legislation in another [68]. The legal distinction between melatonin as a food (dietary supplement) and as a drug is controversial. Consequently, the regulatory status of products containing melatonin varies considerably between countries. In some European countries, melatonin is classified as a medicinal product irrespective of the dose. In other European countries, prescription-only melatonin-containing medicinal products are available alongside FSs containing melatonin, with a maximum permitted daily dose in FSs applying in some countries—e.g., up to 1 mg in Italy (https://fcrinforma.fcr.re.it/area-farmacista/legislazione-farmacia/dispositivi-integratori-e-altri-prodotti/normativa/integratori-alimentari/ministero-della-salute-rivalutazione-degli-apporti-ammessi-di-melatonina-negli-integratori-aliment/, accessed on 2 October 2026) or less than 2 mg in France (https://www.anses.fr/en/content/anses-recommends-certain-populations-avoid-consumption-food-supplements-containing-0, accessed on 2 October 2026)—whereas no specific maximum dose applies in some countries [69,70]. In the United States, melatonin is classified and regulated solely as a dietary supplement and is commercially available over the counter in a wide range of doses [71]. In Canada, melatonin is regulated as an over-the-counter natural health product for adults, alongside prescription-only medicinal products for specific indications in adults and children [72].
In the EU, the regulatory framework permits certain health-related advertising claims—known as “health claims”—for food or its constituents (nutrients or other substances), on the condition that they are substantiated by scientific evidence assessed by the European Food Safety Authority (EFSA) [73,74]. Health claims are any statements used on labels, in marketing or in advertising of foods suggesting or implying that consumption of a food or one of its constituents is associated with a health benefit [73,75]. Following scientific assessments by EFSA, two specific health claims for melatonin—reducing sleep onset latency (requiring 1 mg close to bedtime) and alleviating subjective jet lag (requiring at least 0.5 mg)—are authorised in the EU [76,77]. Importantly, the conditions of use established for existing authorised melatonin health claims should not be regarded as safety thresholds. EFSA’s scientific assessment in the context of health claim evaluations specifically addresses the substantiation of beneficial effects [78]. The scientific assessments on health claims, however, do not include a safety assessment in order to establish health-based guidance values or a tolerable upper intake level for constituents of food (supplements).

4.2.2. Product Characteristics

Melatonin-containing FSs have become increasingly available on the market in recent years [79]. For this review, a query was submitted to the Mintel Global New Products Database, which tracks product introductions in consumer-packaged goods markets worldwide, to determine whether this trend was also reflected in the number of launches of new FSs containing melatonin as an ingredient. The Mintel database includes packaged products newly placed on the market and classifies them, among other things, according to their ingredients. The product search was conducted exclusively within the main categories of “Healthcare” and “Beverages”, and the following subcategories were searched: Tea and Other Hot Drinks, Vitamins and FSs, Sleep Aids and Nutritional and Meal Replacement Drinks. Products added to the database via trade fairs or secondary research were excluded. Mintel distinguishes between five main categories of product launch. These are: new product; new variety/range extension; new packaging; new formulation; and relaunch. The ‘new product’ launch type was taken into account as an additional analysis criterion. The query submitted to the Mintel database in relation to new melatonin-containing FSs brought to market in Germany in the period between January 2020 and August 2026 produced 199 food product entries. Of these, 63 were stated to be new products. Over the seven years (2020–2026), there was an increase in the number of new products.
A wide range of FSs containing melatonin is marketed in various forms, such as tablets, capsules, drops, sprays, powders or soft chewing gum, and is available from drugstores, pharmacies and online retailers [80]. Manufacturers advertise them as helping people fall asleep and/or improving their sleep, often presenting them as natural and supposedly safe sleeping aids.
Melatonin-containing FSs are available in different formulations, and manufacturers may claim that individual products have immediate-release, sustained-release or combined release characteristics. However, unlike for medicinal products containing melatonin, the pharmacokinetic characteristics of specific melatonin-containing FSs are generally not investigated in clinical trials before marketing. This is particularly relevant because, as described above, the specific formulation can substantially affect the pharmacokinetic properties of melatonin and its systemic exposure, e.g., the extent to which administration results in supraphysiological melatonin plasma levels and whether these elevated levels persist over a longer period of time, potentially extending into daytime hours. These differences may consequently impact possible adverse health effects of melatonin.
To characterise the range of melatonin doses in food supplements marketed in Germany, a structured market survey was conducted on 24 September 2026. Sources comprised the two largest German online pharmacies by revenue, a major general online marketplace, and the Mintel Global New Products Database, a commercial market research database tracking consumer product launches (coverage period January 2022 to September 2026). Across these sources, labelled daily doses of melatonin-containing food supplements ranged from 0.1 mg to 5 mg per recommended daily dose; the majority of products were labelled with a daily dose of 1 mg. A recent market surveillance study by official medicines control laboratories examining the circulation of illicit nootropics in different product categories across European and Australian markets revealed high doses of melatonin in products marketed as FSs, with some exceeding 10 mg of melatonin per unit [81]. Consequently, the recommended daily dose of some melatonin-containing FSs on the market is comparable to, or even far exceeds, the usual or maximum recommended daily dose of melatonin in medicinal products. FSs containing higher doses of 10 mg or more of melatonin are particularly available on online marketplaces, where products are offered by a range of third-party sellers, as has also been shown by Vanhee et al. [69].
Whereas the content of active substances in authorised medicinal products is strictly regulated by pharmacopoeial uniformity and assay requirements—namely an assay limit, set out in the individual Ph. Eur. monographs, of typically 95–105% of the label claim at batch level [82], and the uniformity-of-dosage-units criteria of Pharmacopoea Europaea (Ph. Eur.) general chapter 2.9.40 [83], under which the acceptance value of individual dosage units must not exceed the prescribed limits (L1 = 15.0, L2 = 25.0), corresponding to unit contents within 85–115% and 75–125% of the mean sample content, respectively—FSs are not subject to any legally binding content tolerances under EU law. For non-vitamin ingredients such as melatonin, even the non-binding scientific recommendations (±20–50% for vitamins and minerals) (https://food.ec.europa.eu/system/files/2016-10/labelling_nutrition-vitamins_minerals-guidance_tolerances_1212_en.pdf, accessed on 2 October 2026) do not apply, leaving the declared content essentially unregulated. Indeed, in addition to variability in recommended doses, serious concerns have been raised regarding the accuracy and consistency of the melatonin content of FSs. Several studies have demonstrated significant deviations between the claimed and actual melatonin content. A Canadian study found that in 31 commercially available melatonin-containing FSs, the measured melatonin content ranged from −83% to +478% of the labelled melatonin content on the packaging, with significant lot-to-lot variability for individual products of up to 465% [84]. Melatonin preparations are frequently available as gummies, which carry a risk of inadvertent intake by children owing to their potential to be mistaken for sweets [85,86,87].
Another study analysed 25 FSs specifically with a gummy formulation available in 2022 in the US and labelled to contain 1–10 mg of melatonin per dose [88]. The analysed melatonin quantity ranged from 1.3 to 13.1 mg per dose, with melatonin contents ranging from 74% to 347% of the declared melatonin amounts. Another recent US study focused on FSs marketed for children and analysed 110 products [89]. The authors found a median concentration of 1.7 mg of melatonin per dose (range: 0.042–50 mg/dose), with melatonin contents ranging from 0% to 667% of the label declaration. Higher actual melatonin content than the product label claims was found, especially in products with gummy formulations. Such deviations are plausible in light of the pharmaceutical technology of gummy formulations: the active ingredient must be distributed homogeneously in a viscous gelatin or pectin matrix that sets rapidly upon cooling, which makes uniform dosing of finely distributed actives technically demanding. Manufacturing and testing challenges of this kind are well documented for gummy dosage forms and can compromise dose uniformity and lot-to-lot consistency, particularly in the absence of legally binding content tolerances for FSs [90,91,92,93].
Regarding potential deviations of melatonin content in FSs available in Europe, a Belgian study examined 50 products available on the European online market—25 were sourced from a legal supply chain and 25 from a suspected illegal supply chain—with the latter claiming to contain more than 1 mg of melatonin per daily dose [69]. The label accuracy of the samples originating from the legal supply chain ranged from 71% to 182% (median amount: 0.24 mg, ranging from 0.11 to 2.5 mg of melatonin per daily dose), whereas products from the suspicious supply chain had label accuracy variations ranging from 82% to 172% (median amount: 4.58 mg, ranging from 0.91 to 23.43 mg of melatonin per daily dose). The authors found that products with high melatonin content frequently originated from the USA. Overall, these studies indicate that the use of FSs carries a risk of unpredictable exposure to melatonin.
In contrast to melatonin-containing medicinal products, which use melatonin as their sole active substance, melatonin-containing FSs often contain additional ingredients. One study identified serotonin as a contaminant in 26% of tested melatonin-containing supplements, which was not declared on the label [84]. Other products frequently contain co-formulations with substances that are marketed as having additional relaxing effects. These include plant extracts such as valerian, lemon balm, hops, passion flower, ashwagandha or lavender, as well as other ingredients such as cannabidiol, L-theanine or L-tryptophan [88,89]. However, studies systematically investigating the health effects of such co-formulations are lacking. Therefore, interactions or synergistic effects of these substances with melatonin, including an increased sleep-promoting effect or impairment of alertness, cannot be excluded and warrant caution.

4.2.3. Pattern of Use

Unlike medicinal products, FSs can be purchased over the counter without a prescription and can therefore be used without prior medical advice or medical monitoring [94]. Consequently, how melatonin-containing FSs are used, including the dosage, frequency and duration, is largely determined by the individual consumer. This may lead to prolonged or uncontrolled use, i.e., use that is not medically supervised, particularly among individuals who have difficulty falling or staying asleep. This may result not only in prolonged exposure to melatonin but also in a delay in the identification and treatment of the underlying causes of sleep disturbances. Investigations on melatonin use in children in the US and Australia show that melatonin is often used by caregivers without any medical recommendation or monitoring [95,96,97]. Overall, caregivers consider melatonin to be “natural” and “safe” [95,98].
Specific population-based data to estimate the current consumption patterns of melatonin-containing FSs, e.g., from consumer surveys, in Europe are lacking. The Consumer Monitor of the German Federal Institute for Risk Assessment (BfR), a representative population survey, assessed familiarity with such products in August 2024—56% of respondents in Germany had heard of melatonin-containing FSs (https://www.bfr.bund.de/publikationen/bfr-verbrauchermonitor-082024/, accessed on 2 October 2026). Available investigations from the US indicate an increasing use of melatonin-containing FSs over recent decades in the whole population and, in particular, among children and adolescents [86,99]. Data from the National Health and Nutrition Examination Survey (NHANES) indicate that melatonin-containing FSs are among the 15 most commonly used FSs in the United States [100]. During the 2007–2008 survey period, approximately 0.4% of surveyed US adults reported melatonin use, whereas this proportion increased to 4.3% in 2017–2018 [101]. Another analysis based on the NHANES data reported an increase in self-reported use of melatonin doses greater than 5 mg/d in adults over time, although the overall use of high-dose melatonin supplementation remained low [102]. Based on NHANES data, 1.3% of children and adolescents used melatonin-containing dietary supplements in the past 30 days during 2017–2018, with the highest use reported among those aged 12–19 years [103]. A more recent online survey of parents of 933 US children aged 1–13 years, conducted in 2023, provided further information on the use of melatonin-containing FSs among younger children [104]. Within the 30 days preceding the survey, approximately one in five children aged 10–13 years (19.4%), 18.5% of children aged 5–9 years and 5.6% of children aged 1–4 years had reportedly received a melatonin-containing dietary supplement from their parents. Gummies (64.3%), followed by chewable tablets (27.0%), were the most frequently reported forms used. The median duration of melatonin use was at least one year, with a maximum median duration of 21 months among children aged 10–13 years (range: 0–108.0 months). Reported median daily doses were 0.5 mg (range: 0.25–2.0 mg) in children aged 1–4 years, 1.0 mg (range: 0.25–5.0 mg) in children aged 5–9 years and 2.0 mg (range: 0.25–10.0 mg) in children aged 10–13 years. According to parental reports, melatonin was most commonly administered either once per week or daily [104]. In addition to the increased intentional use, there are reports of an increase in accidental intake of melatonin-containing supplements, especially in young children, as documented in the US (see Section 5.3). Melatonin preparations in the form of gummies, in particular, carry a high risk of inadvertent intake by children owing to their potential to be mistaken for sweets [85,86,87].
Overall, the regulatory status as well as product characteristics and usage patterns of melatonin-containing FSs differ notably from those of authorised melatonin-containing medicinal products. In particular, the variation in formulation, dosage and product composition of melatonin-containing supplements and the fact that they can be used without medical supervision may result in uncontrolled exposure to melatonin and potential adverse health effects.

5. Health Risks Associated with Melatonin Intake

5.1. Findings from Human Studies and Reports—Healthy Adult Individuals

Previous studies have indicated that 0.3 mg of melatonin is the minimum efficacious single dose of melatonin to promote sleep [21,43,105]. Acute adverse effects that were frequently observed in healthy adults after taking melatonin in various doses (from 0.5 mg or more) included sleepiness, headaches, reduced subjective and experimentally determined alertness, prolonged reaction times, low blood pressure, reduction in body temperature, nightmares, weakness, morning drowsiness and unsteadiness [20,105,106,107,108,109].
A systematic review that appeared in 2022 investigated the safety aspects for adults of relatively high melatonin doses (≥10 mg/day) over an extended period (three months and longer). The review covered 79 studies with 3861 adult test subjects; of these, 15 studies covered an intervention duration of three months or more, and 14 studies included healthy adults. Only four studies were classified by the authors as having a low risk of bias. These studies suggested that administering exogenous melatonin did not lead to a detectable increase in serious adverse effects (SAEs) or events (rate ratio = 0.88 [CI: 0.52, 1.50]), nor to a higher number of participants dropping out due to adverse effects (rate ratio = 0.93 [CI: 0.24, 3.56]). However, due to the broad confidence intervals and limited evidence base (four studies involving approximately 400 participants), a clinically significant increase in SAEs cannot be ruled out, and the evidence is inconclusive. Nevertheless, melatonin administration was found to significantly increase the risk of adverse effects such as sleepiness, headaches, and dizziness (rate ratio = 1.40 [CI: 1.15, 1.69]). The authors noted that only a few studies were available from which robust conclusions could be drawn about melatonin’s safety profile [110].
A retrospective pharmacovigilance study analysing 35,479 adverse event reports for exogenous melatonin from WHO-VigiBase (January 1996–September 2022) identified 21 safety signals—including precocious puberty, tic, growth retardation, and disturbance in social behaviour—that were consistent across both comparator settings (all other drugs and other sleep medications), with several signals predominantly affecting paediatric populations and absent from current regulatory drug labels. Among predefined adverse events of special interest, nightmares (adjusted ROR 4.90; 95% CI 4.37–5.49) and abnormal dreams (3.68; 3.19–4.25) remained significant even when compared to other sleep medications, whereas accidents/injuries and falls were attenuated, suggesting a safety profile broadly comparable to other hypnotics. These findings are particularly relevant given the widespread over-the-counter availability of melatonin as a dietary supplement in many countries, where unsupervised self-medication—especially in children—may expose users to identified risks without adequate monitoring or label warnings [111].

5.1.1. Glucose Homeostasis and the Risk of Type 2 Diabetes

Studies testing glucose tolerance and insulin secretion/insulin sensitivity indicate that melatonin intake at doses of 1 or 4 mg/day has an acute effect on glucose homeostasis in healthy adults. These acute effects are the most well-documented metabolic consequences of taking melatonin. However, it is unclear whether this translates into an increased long-term risk of developing type 2 diabetes mellitus (T2DM); the available evidence does not permit such a conclusion to be drawn. This raises the question of whether long-term use of melatonin-containing products might increase the risk of developing T2DM and whether individuals who carry the T2DM risk allele (corresponding to a variant of the melatonin receptor 2 (MTNR1B) gene locus) are at particular risk. It should be noted that this risk allele is relatively common in the European population, affecting at least 30% of individuals, based on “minor allele frequency” [112]. A specific MTNR1B allele has been linked to an increased risk of T2DM [6].
The common MTNR1B variant rs10830963 can delay the onset of melatonin secretion and prolong elevated melatonin levels. This disrupts the circadian rhythm and elevates fasting glucose, increasing insulin resistance [113]. Conversely, melatonin can inhibit insulin secretion, which can be beneficial during nocturnal fasting. However, taking melatonin in the evening near mealtimes can impair glucose tolerance. Over time, this metabolic disruption may lead to suboptimal glycaemic regulation or the progression of T2DM [114]. However, it must be emphasised that this mechanism has been established only at the level of acute glucose tolerance testing. Extrapolating from such single-dose perturbations to the cumulative risk of incident T2DM without evidence of sustained glycaemic deterioration over time is not warranted.
The apparent discrepancies between the summarised studies are best explained by fundamental differences in design, dosage, timing, follow-up, study populations, and genetic stratification, rather than by mutually exclusive findings. In three large US prospective cohorts with up to 23 years of follow-up, regular self-reported melatonin supplement use was not associated with an increased risk of developing type 2 diabetes (adjusted hazard ratio (HR) 0.98, 95% confidence interval (CI) 0.86–1.12) or cardiovascular disease (adjusted HR 0.94, 95% CI 0.83–1.06). However, there was some evidence to suggest that melatonin use might reduce the risk of type 2 diabetes (T2DM) associated with long-term rotating night shift work [115]. These cohort analyses reflect habitual, largely uncharacterised, real-world use in general populations and could not be stratified by MTNR1B genotype. A systematic review and meta-analysis of 30 randomised controlled trials in adults found that melatonin supplementation significantly reduced fasting blood glucose, insulin, and HOMA-IR and slightly improved insulin sensitivity. However, there was no significant effect on HbA1c, and the results must be interpreted with caution due to high heterogeneity [116]. These trials predominantly enrolled individuals with cardiometabolic risk factors and used heterogeneous doses and durations. They also assessed surrogate parameters over short periods rather than incident disease. In contrast, a randomised, double-blind, placebo-controlled crossover trial involved 21 healthy participants (10 carriers and 11 non-carriers of the MTNR1B T2DM risk allele). Within a highly controlled five-day laboratory setting, the participants received either 5 mg of oral melatonin or a placebo on two non-consecutive days. Glycaemic dynamics were assessed using insulin-modified intravenous glucose tolerance testing. A single dose of melatonin acutely impaired glucose tolerance and reduced glucose-stimulated first-phase insulin secretion by approximately 40%, but only in individuals with the risk allele. This suggests that blunted beta-cell responsiveness to glucose and impaired insulin feedback inhibition are mechanisms through which exogenous melatonin can negatively impact glucose homeostasis [117]. While this experiment documents an acute, genotype-dependent effect under controlled conditions using a sensitive dynamic test, it does not itself establish an increased risk of manifest disease.
Taken together, the documented acute, genotype-dependent impairment of β-cell function and the potential long-term risk of T2DM, particularly in risk-allele carriers, must be clearly distinguished from the existing evidence gaps. As no long-term study has yet been conducted that stratifies by MTNR1B genotype, and no trial has used incident T2DM as an endpoint, it remains unclear whether risk-allele carriers are a susceptible subgroup for whom chronic melatonin use poses a relevant metabolic risk.

5.1.2. Investigations into Effects on the Endocrine System in Healthy Adults

Investigations carried out on adult test subjects, in which the plasma levels of relevant developmental and reproductive hormones (growth hormone (GH), prolactin (PRL), luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol and testosterone) were determined in relation to exogenously administered melatonin, yielded inconsistent results [118,119,120,121,122,123]. Overall, the extent to which regular melatonin intake over an extended period affects human fertility remains unclear [122,124,125]. Furthermore, past studies have investigated whether high doses of melatonin could be used as a contraceptive for both women and men [120,125].
Fundamental investigations into the effects of exogenous melatonin on reproductive hormones (growth hormone, prolactin, luteinising hormone, follicle-stimulating hormone, oestradiol and testosterone) in adults were conducted between the 1980s and 2000s. These studies, which included trials exploring the contraceptive potential of high-dose melatonin, have not been replicated in contemporary study populations using modern analytical methods.
Recent studies have begun to address this evidence gap. In a randomised, placebo-controlled trial, Saraiva et al. (2026)[126] administered 0.3 mg of melatonin to 46 climacteric nurses working fixed shifts. Blood samples were collected before and after the intervention to measure levels of luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol and progesterone. Melatonin was found to reduce climacteric symptoms by 15.8% compared with the placebo group (p = 0.01). However, no significant changes were observed in any of the measured reproductive hormone concentrations [126]. Similarly, a meta-analysis of eight randomised controlled trials involving menopausal women (n = 812) examined the effects of melatonin doses ranging from 1 to 5 mg over intervention periods spanning 3 to 12 months. This analysis also found no significant changes in oestradiol levels (weighted mean difference: 0.016 pg/mL [95% CI: −1.220 to 1.252, p = 0.980]). While melatonin was found to improve physical menopausal symptoms, it had no significant impact on general menopausal symptoms, sleep quality, or mood states [127]. Taken together, these recent studies provide no indication of clinically relevant melatonin-induced changes in reproductive hormones at doses of up to 5 mg over periods of up to one year. However, several limitations must be considered: the individual trials were not designed as endocrine safety studies; the populations studied were women of climacteric or menopausal age, rather than healthy young adults of both sexes; hormonal assessment was largely confined to oestradiol; and in the trial by Saraiva et al., assessment was confined to a single post-intervention measurement at a low dose. No trial systematically monitored additional endocrine parameters, such as prolactin, growth hormone, or thyroid function. Therefore, systematic, safety-oriented endocrine monitoring during regular, long-term melatonin intake in healthy individuals of both sexes is still lacking, and the aforementioned data gap persists.
Some studies have investigated the possible effects of melatonin intake on thyroid hormones. With regard to TSH, no significant effects were observed following a one-off intake or intake over a period of up to two months of 1–10 mg of melatonin [124,128,129,130,131,132].
Overall, insufficient data are currently available from long-term studies investigating the possible influence of long-term administration of exogenous melatonin on physiological hormonal control.

5.1.3. Cardiometabolic Health

The effects of melatonin supplementation on cardiometabolic health remain poorly understood. In its 2025 scientific statement, the American Heart Association emphasises that circadian health is a distinct determinant of cardiometabolic health, with disruptions of circadian rhythmicity—driven by modifiable behaviours such as light exposure, meal timing, physical exercise, and sleep timing—adversely affecting cardiometabolic function and increasing the risk of obesity, type 2 diabetes, hypertension, and cardiovascular disease. As the endogenous neurohormone conveying circadian timing to peripheral physiologic processes, melatonin occupies a central position in this system [133].
At the American Heart Association conference in 2025, Nnadi et al. presented preliminary, not yet peer-reviewed conference data from a longitudinal study (based on data from anonymised electronic health records) suggesting that long-term (>365 days) melatonin supplementation is associated with an 89% increased risk of heart failure (diagnosis of heart failure: 4.6 per cent vs. 2.7 per cent; hazard ratio: 1.89; 95% CI: 1.78–2.00), a threefold increase in hospital admissions due to heart failure and a doubling of all-cause mortality over a five-year period in adult patients with insomnia [134]. However, these findings are based on a retrospective analysis of electronic health records and should be interpreted with caution. The authors themselves emphasise that the study design cannot establish causality. Key limitations include exposure misclassification, confounding factors such as the severity of insomnia and psychiatric comorbidity, detection bias, and possible reverse causality.
Conversely, a subsequent analysis of the nationally representative NHANES cohort (1999–2018) found no significant association between recent melatonin use and prevalent cardiovascular disease or heart failure, highlighting that observational associations are particularly vulnerable to confounding by indication, reverse causality, and exposure misclassification—especially given that over-the-counter melatonin use is frequently undocumented in the medical records of control patients [135,136]. Consistently, a further retrospective observational study reported no independent association between melatonin use and heart failure [137], while a meta-analysis of randomised trials in patients with cardiovascular disease suggested possible benefits for left ventricular function and quality of life [136].
In summary, preliminary observational data suggest an association between long-term melatonin supplementation and an increased risk of heart failure, hospitalisation due to heart failure, and all-cause mortality. However, subsequent analyses found no significant or independent association with cardiovascular disease or heart failure. Nevertheless, such observational associations are particularly vulnerable to confounding by indication, reverse causality and exposure misclassification. In fact, a meta-analysis of randomised trials in patients with cardiovascular disease suggested potential benefits.

5.1.4. Pharmacokinetic and Pharmacodynamic Interactions

As cytochrome P450 isoenzymes (CYP) have a central role in the metabolisation of a wide range of pharmacological or foreign substances (xenobiotics), interactions may generally occur when certain substances are administered simultaneously. This may be due to those substances being metabolised by the same enzyme, or due to certain active substances inducing the formation of cytochrome P450 isoenzymes or inhibiting their function. This can lead to reduced or enhanced substance metabolisation, which can result in higher or lower plasma levels of the active substances and consequently influence the (adverse) health effects of one or both active substances. In the case of melatonin, interactions may occur with parallel administration of substances or substance components that are metabolised by, or affect, its main metabolising CYP enzymes, specifically CYP1A2 (see Section 3.2).
According to the EMA, pharmaceutical active ingredients that, on the basis of pharmacokinetic interactions, might raise plasma melatonin levels if used alongside melatonin include the antidepressant fluvoxamine, the photosensitising active ingredients 5- or 8-methoxypsoralen, exogenously administered oestrogens (as contraceptives or hormone replacement therapy), the H2 antihistamine cimetidine and quinolone antibiotics [138]. Although there is a lack of information about adverse effects resulting from pharmacokinetic interactions, the available information provides grounds for caution when combining melatonin with the above-mentioned (pharmaceutical) substances.
Furthermore, caffeine intake increases melatonin bioavailability by inhibiting hepatic melatonin metabolism [139]. Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke, on the other hand, can induce CYP1A2 [140], leading to increased melatonin clearance and hence decreased melatonin levels. Plasma levels of exogenously administered melatonin in male test subjects who had given up smoking were on average three times higher than when they were smokers [141].
According to the EMA, pharmacodynamic interactions, characterised by an intensified sedative effect, were observed when melatonin was taken (as a medicinal product) in parallel with the pharmaceutical substances thioridazine (neuroleptic), imipramine (antidepressant), or benzodiazepine and non-benzodiazepine hypnotics [23,32]. For example, combined administration of 2 or 5 mg of melatonin with 10 mg of zolpidem was shown to result in greater impairment of alertness, cognitive performance and coordination than zolpidem alone, or in more frequent reports of nausea, confusion and morning tiredness than melatonin alone [23,142,143]. According to the Summary of Product Characteristics of Circadin, the parallel use of melatonin and the tricyclic antidepressant imipramine led to excessive tranquilisation and increased difficulties in accomplishing tasks, while co-administration with the neuroleptic thioridazine led to increased drowsiness compared with imipramine or thioridazine use alone, respectively [23].
Although information about adverse effects resulting from pharmacokinetic interactions is scarce, the available data on pharmacokinetic and pharmacodynamic interactions provide grounds for caution when using melatonin alongside the aforementioned pharmaceutical substances.

5.2. Pregnant and Breastfeeding Women

Studies on melatonin kinetics and placental transfer in animals and humans show that melatonin can rapidly cross the placenta without biotransformation and thus be transferred to the foetus/newborn [144,145,146,147]. In one human pharmacokinetic study, changes in maternal physiological serum levels of melatonin, as well as levels after exogenous melatonin administration, were rapidly reflected in the foetal circulation, as assessed in umbilical serum [144].
As shown in human studies on melatonin physiology during pregnancy, maternal nocturnal plasma melatonin levels increase, particularly during the late third trimester, reaching their highest levels shortly before birth and declining postpartum [148,149,150]. Melatonin synthesis in the placenta may contribute to this increase and has been suggested to play an antioxidant and anti-inflammatory role and to contribute to the regulation of the foetal circadian rhythm [148]. Data from observational studies indicate lower melatonin levels in women with preeclampsia compared with women with uncomplicated pregnancies [151,152].
Only a few clinical interventional studies have investigated the effects of exogenous melatonin during pregnancy, focusing on its therapeutic use. In a phase I trial, 20 women with early-onset preeclampsia received a total daily dose of 30 mg of melatonin (sustained-release formulation) from recruitment until delivery. Infants of melatonin-treated mothers had a higher rate of being small for gestational age at birth (<10th percentile) compared to historical controls [153]. In a recent double-blind, placebo-controlled trial, 189 women without significant maternal or perinatal complications received 10 to 60 mg of melatonin as an adjuvant during induction of labour. Neonates of melatonin-treated mothers were more likely to require admission to a special care nursery, mainly for hyperglycaemia monitoring, leading to the authors’ suggestion that intrapartum melatonin use may be associated with neonatal hypoglycaemia [154]. However, the results of these trials involve specific clinical conditions or situations and doses that may not reflect typical use of food supplements. The results of these studies cannot, therefore, be generalised directly to all pregnant or breastfeeding women.
Human observational studies involving the analysis of breast milk and maternal serum have demonstrated that endogenous melatonin is also detectable in human breast milk, showing circadian variation with higher concentrations at night, and variations across gestational age and stage of lactation have been reported [149,152,155,156]. One small observational study found the melatonin concentration of nighttime breast milk to be about 35% of the maternal serum concentration [157]. Therefore, exogenous melatonin may also be transferred into breast milk. However, up to now, no clinical trials investigating the pharmacokinetics or safety of exogenous melatonin use during breastfeeding have been found in the literature. Only one identified case report has examined the use of maternal exogenous melatonin during breastfeeding: it described recurrent bleeding episodes in an 18-month-old infant after nursing, which resolved after the mother discontinued her (unspecified) melatonin use. The authors suggested a possible association between maternal melatonin use and exposure to melatonin via breast milk, potentially affecting platelet aggregation [158].
Taking into account the fact that the foetal and neonatal pineal gland is not able to produce melatonin rhythmically for several months, leading to very low endogenous melatonin levels during this time, as well as a very limited capacity to metabolise melatonin (see Section 3.2), exposure to exogenous melatonin via maternal use during pregnancy or breastfeeding could potentially result in relatively high melatonin exposure and potentially persisting supraphysiological melatonin levels in the foetus or infant. Based on these considerations and given the overall scarcity of clinical data on the safety of melatonin intake during pregnancy and breastfeeding, pregnant or breastfeeding women or women planning to become pregnant should avoid the uncontrolled use of melatonin-containing supplements as a precautionary measure.

5.3. Healthy Children

Melatonin-containing preparations are increasingly used in children—both intentionally, as a sleep aid, and unintentionally, through accidental ingestion. This section addresses potential health risks due to both pathways of exposure in children, with a focus on typically developing (healthy) children, while some of the surveillance data cited below cover paediatric populations irrespective of health status.
As mentioned above, given the comparatively very limited metabolic capacity for melatonin in babies and infants, exogenous melatonin administration may result in reduced clearance and potentially prolonged exposure. Consequently, plasma melatonin levels may remain elevated for longer periods, potentially resulting in prolonged exposure to supraphysiological levels of melatonin, even at doses regarded as relatively low in older children and adults.
A study published by the Centers for Disease Control and Prevention (CDC) in its Morbidity and Mortality Weekly Report estimated emergency department (ED) visits for unsupervised melatonin ingestion by infants and children aged ≤5 years in the United States between 2019 and 2022, using national ED surveillance data (NEISS-CODES). An estimated 10,930 ED visits (95% CI = 7609–14,251) occurred in this period, accounting for 7.1% of all ED visits for unsupervised medication exposure in this age group. Approximately half (52.4%) of these visits involved children aged 3–5 years, and the vast majority (93.5%) did not result in hospitalisation. Solid dosage forms were implicated in 95.7% of visits, with gummy formulations being the most commonly documented (47.3%), and access to ≥10 units was documented in more than one-third (35.8%) of solid-product ingestions [85].
Similarly, an analysis of all melatonin exposures in individuals under 19 years reported to US poison centres between 2012 and 2021 identified 260,435 cases, corresponding to 2.25% of all paediatric reports. Most cases involved children under 5 years of age (84%), were unintentional (94%), and occurred at home (99%). While 84.4% of cases were asymptomatic with recovery at home, 27,795 children were treated at a healthcare facility; of these, 14.7% required inpatient treatment, 1% (287 cases) required intensive care, and five children required mechanical ventilation. Two deaths (age ≤ 2 years) were reported. The most frequent adverse effects concerned the central nervous, gastrointestinal, and cardiovascular systems. The authors noted that self-reported data may underestimate actual exposure, case reports could not be verified, and causality between melatonin and the deaths could not be established [86].
Deaths of young children have also been reported in association with melatonin ingestion. Bishop-Freeman et al. described seven unexplained paediatric deaths of infants and toddlers aged two months to three years investigated since 2015 by the North Carolina Medical Examiner System, in whom exogenous melatonin was detected on postmortem toxicological analysis [159,160]. Although no conclusions regarding causation can be drawn from these reports, they merit attention: they show that melatonin is being given to children, including infants, and serve as a reminder that the easy availability of melatonin preparations and the casual attitude toward them invite improper use, including administration to children by others.
In studies involving intended daily administration of melatonin (for at least several days) in children or adolescents without additional severe comorbidities but with primary sleep disorders, reported adverse effects included, among others, headaches, paleness, dizziness/drowsiness, coldness, gastrointestinal complaints (nausea, diarrhoea, vomiting) and increased urinary urgency or bed-wetting [161,162,163,164,165]. An analysis of spontaneous adverse drug reaction reports in the European Medicines Agency’s EudraVigilance database (177 cases after exclusion of reports involving other suspected or concomitant drugs) compared suspected neuropsychiatric adverse drug reactions of melatonin between children and adults. While the spectrum of reported adverse reactions overlapped between children and adults, symptoms associated with increased central nervous system excitability—such as aggression (p < 0.001), abnormal behaviour (p = 0.038) and psychomotor hyperactivity—were reported more frequently in children [166].

5.3.1. Long-Term Hormonal and Pubertal Effects

Given that melatonin, as a hormone, is involved in modulating a wide range of processes in the body, and taking into account evidence from studies in adults that melatonin may, amongst other things, affect blood concentrations of growth hormone (GH) or aspects of the sex hormone system (see Section 5.1.2), the possibility of long-term effects of exogenous melatonin on growth, development and/or reproductive functions should be taken into account, particularly in children and adolescents. Physiological age-dependent nighttime endogenous melatonin peak plasma concentrations are highest in children aged four to seven years and decline steadily thereafter, with this decline being particularly pronounced from the prepubertal phase to puberty [3,13,167]. It is therefore unclear to what extent orally administered melatonin might influence individual hormonal or pubertal development. Only a few clinical studies have so far investigated pubertal development (as a secondary endpoint/outcome) as a function of long-term exogenous melatonin administration; these are limited in meaningfulness due to small sample numbers, an incomplete follow-up period and inadequate characterisation or measurement of the onset of pubertal maturation [168]. In a recently published study using data from the Adolescent Brain Cognitive Development (ABCD) study, Sadikova et al. emulated a sequence of hypothetical randomised trials to test whether sustained melatonin supplement use over 38 months affects pubertal timing, measured as pubertal onset in 3134 males and menarche in 4424 females based on parent-reported Pubertal Development Scale data. Neither intention-to-treat nor per-protocol analyses showed any effect of melatonin use on pubertal onset in males or on menarche in females. By contrast, conventional Cox models comparing ever-users with never-users suggested a delayed menarche among the 7.7% of female melatonin users (HR = 0.80, 95% CI 0.69–0.94). Key limitations include the reliance on parent-reported Pubertal Development Scale data rather than clinician-assessed Tanner staging, residual confounding, and the small number of melatonin initiators (186 males, 333 females), which limits statistical power [169].

5.3.2. Evidence Gaps

To date, most randomised controlled trials on the use of melatonin in paediatrics have been conducted in children with neurological conditions or developmental disorders [170]. Overall, there is a lack of consensus on the long-term effects of melatonin, which have been insufficiently studied and warrant additional investigation, particularly in children and adolescents [61,99,171,172]. A systematic review of 19 studies (2000–2025) revealed a significant increase in the prescription of melatonin, its long-term use, and overdose incidents in young children aged 0–6 years over the past two decades; melatonin is now the leading cause of unsupervised medication exposure and overdose in this age group presenting to emergency departments. However, no trial examined efficacy or safety in children with typical development or measured outcomes beyond two years. These findings suggest that the global increase in melatonin use has exceeded the available evidence on its short- and long-term efficacy and safety [173].
In a technical report commissioned by the International Pediatric Sleep Association (IPSA), Owens et al. analysed the available evidence on melatonin for managing insomnia in typically developing children—where data are sparse or inconclusive, in contrast to children with neurodevelopmental disorders—and derived evidence-based and consensus-based recommendations to guide practitioners in clinical decision-making. In a companion narrative review, the same group characterised paediatric melatonin use as an evolving global concern, noting that while the drug appears generally safe and well tolerated in children with neurodevelopmental disorders, comparable efficacy and long-term safety evidence is lacking for typically developing children, and that rising use has been accompanied by highly variable content in over-the-counter products and increasing accidental ingestions [174,175]. The authors of a systematic review with meta-analysis on the use of melatonin in otherwise healthy children with idiopathic, chronic sleep disorders likewise conclude that melatonin should only be recommended if sleep hygiene measures and non-pharmacological interventions have proved insufficient, that treatment should be as short as possible, and that a medical review should take place after 14 days and after three months [172].

6. Conclusions

As described in this review, the pharmacokinetic properties of exogenous melatonin are characterised by very low and highly variable oral bioavailability (depending on the specific formulation of administered melatonin as well as co-exposure to other substances), rapid hepatic metabolism—primarily via the cytochrome P450 enzyme CYP1A2, which itself exhibits pronounced interindividual variability in activity—and a short elimination half-life, so that comparable oral doses can result in markedly different plasma levels between individuals. Supraphysiological plasma concentrations may occur even at doses below 0.5 mg of melatonin in some individuals, with a higher risk of prolonged supraphysiological levels in certain subpopulations, such as the elderly, infants or genetically slow metabolisers. For healthy children, there is a lack of studies on the pharmacokinetic properties of melatonin.
The regulatory framework for melatonin is correspondingly heterogeneous: depending on the jurisdiction, melatonin is classified either as an FS available over the counter or as a medicinal product subject to prescription and pharmaceutical quality control, which results in inconsistent dose recommendations, variable product quality and largely unrestricted consumer access to melatonin-containing products in some markets.
With regard to acute adverse effects in healthy adults taking melatonin, headache, dizziness, nausea and daytime drowsiness are the ones most frequently reported. Overall, there are no high-quality clinical studies available on the long-term safety of exogenously administered melatonin, particularly in healthy individuals. With regard to cardiovascular outcomes, no conclusion on the cardiovascular risk of melatonin-containing FSs can currently be drawn. With regard to endocrine functions, studies on reproductive and developmental/endocrine parameters in adults have yielded inconsistent results; effects of regular long-term intake on human fertility remain unclear, and long-term data on physiological hormonal control are insufficient. There is also a lack of prospective, controlled, long-term studies in typically developing children that systematically monitor growth, pubertal development, and endocrine parameters.
Overall, based on the available but limited data, uncontrolled long-term use of melatonin-containing FSs is generally not advisable, and certain at-risk groups in the population should be excluded from the uncontrolled, non-medically supervised use of dietary supplements containing melatonin [80]. The recommendations below are categorised according to the primary basis of their evidence: direct clinical evidence; pharmacological rationale derived from the known properties of the substance; and the precautionary principle in the absence of adequate data. This labelling aims to clarify that some of the restrictions are precautionary and do not imply demonstrated harm in the relevant groups.
Caution is advised for individuals with a reduced metabolic capacity for melatonin (e.g., carriers of specific CYP1A2 gene variants in all age groups and older adults), as reduced clearance may result in prolonged systemic exposure and potential next-day carryover of melatonin, with plasma concentrations remaining elevated the following day. This consideration also applies to otherwise healthy individuals, as reduced metabolic capacity may be genetically determined or age-related. Due to the considerable interindividual variability in melatonin metabolism, unsupervised use of melatonin-containing FSs, particularly long-term use, should be approached with caution. Based on the observed acute adverse effects of melatonin, it should also be noted that taking melatonin-containing FSs may impair the ability to drive or perform tasks requiring particular alertness.
Due to the limited data on the safety of melatonin administration, particularly long-term administration, in healthy children and adolescents, and the uncertainty surrounding its potential impact on child development (e.g., linear growth and pubertal development), melatonin-containing FSs should not be used by this age group (precautionary principle). This recommendation is based on the absence of adequate long-term safety data in these populations, rather than on evidence of serious adverse effects under typical conditions of use. In light of the lack of data on the possible health effects of administering melatonin during pregnancy and lactation, the use of melatonin-containing food supplements (FSs) should be restricted for women planning to become pregnant, pregnant women and breastfeeding women. Given the limited capacity for melatonin metabolism in early infancy, this restriction should also apply to infants.
Due to uncertainty regarding the risk of developing T2DM, individuals who are predisposed to T2DM are advised against using melatonin-containing FSs without medical supervision (acute, genotype-dependent clinical findings combined with a pharmacological rationale; long-term risk unproven). Particular caution should be exercised when administering melatonin to people with impaired liver or kidney function, autoimmune diseases or epilepsy (pharmacological rationale for hepatic impairment; precautionary principle for all other conditions). As melatonin undergoes extensive hepatic first-pass metabolism, impaired liver function slows its degradation and prolongs its systemic availability. These individuals should not use melatonin-containing FSs, and the therapeutic use of melatonin should only take place under strict medical supervision.
Due to the potential for interactions between exogenously administered melatonin and various medications, individuals taking other medications are advised to consult a physician before using FSs containing melatonin.
It should be emphasised that the above assessment relates to the pharmacological safety of melatonin as an active substance. This must be distinguished from the risks arising from the inadequate quality control of melatonin-containing food supplements. These risks include inaccurate declaration of melatonin content, variability in dosage forms and actual delivered doses, and the possibility of accidental ingestion by children. In summary, while the acute effects of low-dose melatonin are reported to be generally mild, the limited evidence regarding long-term safety, particularly among children, adolescents, pregnant and breastfeeding women, and other vulnerable groups, together with considerable interindividual variability in melatonin metabolism and pharmacodynamics, suggests adopting a precautionary approach to melatonin-containing FSs.

Author Contributions

V.T. and B.N. contributed to the conceptualisation and design of the review. V.T. drafted the initial manuscript, and B.N. provided critical revisions and edits. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

No new data were created or analysed in this study.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
FS Food supplement
T2DM Type 2 diabetes mellitus
GH Growth hormone
ABCDAdolescent Brain Cognitive Development
HRHazard ratio
CIConfidence interval
IPSAInternational Pediatric Sleep Association
WHOWorld Health Organization
RORReported odds ratio
PRLProlactin
LHLuteinising hormone
FSHFollicle-stimulating hormone
EMAEuropean Medicines Agency
EFSAEuropean Food Safety Authority
CYPCytochrome P450
DLMODim light melatonin onset
PKPharmacokinetics
CDCCenters for Disease Control and Prevention
EDEmergency department
MT1Melatonin receptor type 1
MT2 Melatonin receptor type 2
ADHDAttention-deficit hyperactivity disorder
EUEuropean Union
BfRGerman Federal Institute for Risk Assessment
PAHsPolycyclic aromatic hydrocarbons
MTNR1BMelatonin receptor 1B
NEISS-CODESNational Electronic Injury Surveillance System Codes
RIARadioimmunoassay
ELISAEnzyme-linked immunosorbent assay
GC-MSGas chromatography–mass spectrometry
LC-MS/MSLiquid chromatography–tandem mass spectrometry
SAEsSerious adverse events

References

  1. Rodenbeck, A. Biological principles of sleep and wake. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2011, 54, 1270–1275. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Claustrat, B.; Brun, J.; Chazot, G. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev. 2005, 9, 11–24. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Tordjman, S.; Chokron, S.; Delorme, R.; Charrier, A.; Bellissant, E.; Jaafari, N.; Fougerou, C. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Curr. Neuropharmacol. 2017, 15, 434–443. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Ekmekcioglu, C. Melatonin receptors in humans: Biological role and clinical relevance. BioMed Pharmacother. 2006, 60, 97–108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Claustrat, B.; Leston, J. Melatonin: Physiological effects in humans. Neurochirurgie 2015, 61, 77–84. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Kampmann, U.; Lauritzen, E.S.; Grarup, N.; Jessen, N.; Hansen, T.; Møller, N.; Støy, J. Acute metabolic effects of melatonin-A randomized crossover study in healthy young men. J. Pineal Res. 2021, 70, e12706. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Razavi, P.; Devore, E.E.; Bajaj, A.; Lockley, S.W.; Figueiro, M.G.; Ricchiuti, V.; Gauderman, W.J.; Hankinson, S.E.; Willett, W.C.; Schernhammer, E.S. Shift Work, Chronotype, and Melatonin Rhythm in Nurses. Cancer Epidemiol. Biomark. Prev. 2019, 28, 1177–1186. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Kennaway, D.J.; Stamp, G.E.; Goble, F.C. Development of melatonin production in infants and the impact of prematurity. J. Clin. Endocrinol. Metab. 1992, 75, 367–369. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Ardura, J.; Gutierrez, R.; Andres, J.; Agapito, T. Emergence and evolution of the circadian rhythm of melatonin in children. Horm. Res. 2003, 59, 66–72. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Biran, V.; Decobert, F.; Bednarek, N.; Boizeau, P.; Benoist, J.F.; Claustrat, B.; Barré, J.; Colella, M.; Frérot, A.; Garnotel, R.; et al. Melatonin Levels in Preterm and Term Infants and Their Mothers. Int. J. Mol. Sci. 2019, 20, 2077. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Garofoli, F.; Franco, V.; Accorsi, P.; Albertini, R.; Angelini, M.; Asteggiano, C.; Aversa, S.; Ballante, E.; Borgatti, R.; Cabini, R.F.; et al. Fate of melatonin orally administered in preterm newborns: Antioxidant performance and basis for neuroprotection. J. Pineal Res. 2024, 76, e12932. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Andersen, C.C.; Kjær, E.K.R.; Vase, C.B.; Mathiasen, R.; Debes, N.M.; Jørgensen, N.R.; Jennum, P.J. Melatonin secretion across puberty: A systematic review and meta-analysis. Psychoneuroendocrinology 2025, 173, 107281. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Salti, R.; Galluzzi, F.; Bindi, G.; Perfetto, F.; Tarquini, R.; Halberg, F.; Cornélissen, G. Nocturnal melatonin patterns in children. J. Clin. Endocrinol. Metab. 2000, 85, 2137–2144. [Google Scholar] [CrossRef] [PubMed]
  14. Abdelgadir, I.S.; Gordon, M.A.; Akobeng, A.K. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: A systematic review and meta-analysis. Arch. Dis. Child. 2018, 103, 1155–1162. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Nir, I.; Meir, D.; Zilber, N.; Knobler, H.; Hadjez, J.; Lerner, Y. Brief report: Circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J. Autism Dev. Disord. 1995, 25, 641–654. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. European Medicines Agency (EMA). Melatomed and Associated Names (Melatonin): Article 29(4) Referral—Overview; EMA/REF/0000303296; European Medicines Agency: Amsterdam, The Netherlands, 2026.
  17. Harpsøe, N.G.; Andersen, L.P.; Gögenur, I.; Rosenberg, J. Clinical pharmacokinetics of melatonin: A systematic review. Eur. J. Clin. Pharmacol. 2015, 71, 901–909. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Lalanne, S.; Fougerou-Leurent, C.; Anderson, G.M.; Schroder, C.M.; Nir, T.; Chokron, S.; Delorme, R.; Claustrat, B.; Bellissant, E.; Kermarrec, S.; et al. Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder. Int. J. Mol. Sci. 2021, 22, 1490. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Moroni, I.; Garcia-Bennett, A.; Chapman, J.; Grunstein, R.R.; Gordon, C.J.; Comas, M. Pharmacokinetics of exogenous melatonin in relation to formulation, and effects on sleep: A systematic review. Sleep Med. Rev. 2021, 57, 101431. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Deacon, S.; Arendt, J. Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res. 1995, 688, 77–85. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Zhdanova, I.V.; Wurtman, R.J.; Morabito, C.; Piotrovska, V.R.; Lynch, H.J. Effects of Low Oral Doses of Melatonin, Given 2–4 Hours Before Habitual Bedtime, On Sleep in Normal Young Humans. Sleep 1996, 19, 423–431. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Gooneratne, N.S.; Edwards, A.Y.; Zhou, C.; Cuellar, N.; Grandner, M.A.; Barrett, J.S. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J. Pineal Res. 2012, 52, 437–445. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. European Medicines Agency (EMA). Circadin (Melatonin): EPAR—Product Information, Annex I: Summary of Product Characteristics (SmPC); Annex IIIA: Labelling; Annex IIIB: Package Leaflet; EMEA/H/C/000695; European Medicines Agency: Amsterdam, The Netherlands, 2025.
  24. Seiden, D.J.; Shah, S.M. A Randomized, Crossover, Pharmacokinetics Evaluation of a Novel Continuous Release and Absorption Melatonin Formulation. Prim. Care Companion CNS Disord. 2019, 21, 19m02450. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Thanawala, S.; Abiraamasundari, R.; Shah, R. Comparative Pharmacokinetics of Sustained-Release versus Immediate-Release Melatonin Capsules in Fasting Healthy Adults: A Randomized, Open-Label, Cross-Over Study. Pharmaceutics 2024, 16, 1248. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Mun, J.G.; Wang, D.; Doerflein Fulk, D.L.; Fakhary, M.; Gualco, S.J.; Grant, R.W.; Mitmesser, S.H. A Randomized, Double-Blind, Crossover Study to Investigate the Pharmacokinetics of Extended-Release Melatonin Compared to Immediate-Release Melatonin in Healthy Adults. J. Diet. Suppl. 2024, 21, 182–194. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Ait Abdellah, S.; Raverot, V.; Gal, C.; Guinobert, I.; Bardot, V.; Blondeau, C.; Claustrat, B. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers. Drugs R D 2023, 23, 257–265. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Aldhous, M.; Franey, C.; Wright, J.; Arendt, J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br. J. Clin. Pharmacol. 1985, 19, 517–521. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. European Medicines Agency (EMA). Overview of Comments Received on ‘Melatonin Prolonged Release Tablets 2 mg Product-Specific Bioequivalence Guidance’ (EMA/CHMP/226444/2025); Committee for Medicinal Products for Human Use (CHMP)/Methodology Working Party; EMA/32320/2026; European Medicines Agency: Amsterdam, The Netherlands, 2026.
  30. European Medicines Agency (EMA). Circadin (Melatonin): EPAR—Summary of the European Public Assessment Report (Summary for the Public); EMEA/H/C/000695; Committee for Medicinal Products for Human Use (CHMP); European Medicines Agency: London, UK, 2025.
  31. Cardinali, D.P.; Lynch, H.J.; Wurtman, R.J. Binding of melatonin to human and rat plasma proteins. Endocrinology 1972, 91, 1213–1218. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. European Medicines Agency (EMA). Assessment Report for Circadin, INN-melatonin; Committee for Medicinal Products for Human Use (CHMP); EMEA/H/C/695; European Medicines Agency: London, UK, 2007.
  33. Zaidan, R.; Geoffriau, M.; Brun, J.; Taillard, J.; Bureau, C.; Chazot, G.; Claustrat, B. Melatonin is able to influence its secretion in humans: Description of a phase-response curve. Neuroendocrinology 1994, 60, 105–112. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Rolling, J.; Rabot, J.; Schroder, C.M. Melatonin Treatment for Pediatric Patients with Insomnia: Is There a Place for It? Nat. Sci. Sleep 2022, 14, 1927–1944. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Cruz-Sanabria, F.; Carmassi, C.; Bruno, S.; Bazzani, A.; Carli, M.; Scarselli, M.; Faraguna, U. Melatonin as a Chronobiotic with Sleep-promoting Properties. Curr. Neuropharmacol. 2023, 21, 951–987. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Gunes, A.; Dahl, M.L. Variation in CYP1A2 activity and its clinical implications: Influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008, 9, 625–637. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Ou-Yang, D.S.; Huang, S.L.; Wang, W.; Xie, H.G.; Xu, Z.H.; Shu, Y.; Zhou, H.H. Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population. Br. J. Clin. Pharmacol. 2000, 49, 145–151. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. Monostory, K.; Villapalos Garcia, G.; Koller, D.; Adams, S.; Bousman, C.A.; Tsermpini, E.E.; Whirl-Carrillo, M.; Turner, A.J.; Lauschke, V.M.; Nagy, M.; et al. PharmVar GeneFocus: CYP1A2-Clinical Impact, Genetic Variation, and Updated Nomenclature. Clin. Pharmacol. Ther. 2026, 120, 313–323. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  39. Faber, M.S.; Jetter, A.; Fuhr, U. Assessment of CYP1A2 activity in clinical practice: Why, how, and when? Basic Clin. Pharmacol. Toxicol. 2005, 97, 125–134. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Vural, E.M.; van Munster, B.C.; de Rooij, S.E. Optimal dosages for melatonin supplementation therapy in older adults: A systematic review of current literature. Drugs Aging 2014, 31, 441–451. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  41. Kennaway, D.J. Potential safety issues in the use of the hormone melatonin in paediatrics. J. Paediatr. Child Health 2015, 51, 584–589. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Tuft, C.; Matar, E.; Menczel Schrire, Z.; Grunstein, R.R.; Yee, B.J.; Hoyos, C.M. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults. Clin. Interv. Aging 2023, 18, 49–59. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Fourtillan, J.B.; Brisson, A.M.; Gobin, P.; Ingrand, I.; Decourt, J.P.; Girault, J. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm. Drug Dispos. 2000, 21, 15–22. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Sugaya, K.; Nishijima, S.; Miyazato, M.; Kadekawa, K.; Ogawa, Y. Effects of melatonin and rilmazafone on nocturia in the elderly. J. Int. Med. Res. 2007, 35, 685–691. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Merchant, N.M.; Azzopardi, D.V.; Hawwa, A.F.; McElnay, J.C.; Middleton, B.; Arendt, J.; Arichi, T.; Gressens, P.; Edwards, A.D. Pharmacokinetics of melatonin in preterm infants. Br. J. Clin. Pharmacol. 2013, 76, 725–733. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Sonnier, M.; Cresteil, T. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J. Biochem 1998, 251, 893–898. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Carloni, S.; Proietti, F.; Rocchi, M.; Longini, M.; Marseglia, L.; D’Angelo, G.; Balduini, W.; Gitto, E.; Buonocore, G. Melatonin Pharmacokinetics Following Oral Administration in Preterm Neonates. Molecules 2017, 22, 2115. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Paditz, E.; Renner, B.; Koch, R.; Schneider, B.M.; Schlarb, A.A.; Ipsiroglu, O.S. The Pharmacokinetics, Dosage, Preparation Forms, and Efficacy of Orally Administered Melatonin for Non-Organic Sleep Disorders in Autism Spectrum Disorder During Childhood and Adolescence: A Systematic Review. Children 2025, 12, 648. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  49. Braam, W.; Keijzer, H.; Struijker Boudier, H.; Didden, R.; Smits, M.; Curfs, L. CYP1A2 polymorphisms in slow melatonin metabolisers: A possible relationship with autism spectrum disorder? J. Intellect. Disabil. Res. 2013, 57, 993–1000. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  50. Zhou, S.F.; Wang, B.; Yang, L.P.; Liu, J.P. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev. 2010, 42, 268–354. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Kennaway, D.J. Measuring melatonin by immunoassay. J. Pineal Res. 2020, 69, e12657. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Kennaway, D.J. A critical review of melatonin assays: Past and present. J. Pineal Res. 2019, 67, e12572. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Skubic, C.; Zevnik, U.; Nahtigal, K.; Dolenc Grošelj, L.; Rozman, D. Circadian Biomarkers in Humans: Methodological Insights into the Detection of Melatonin and Cortisol. Biomolecules 2025, 15, 1006. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Butiulca, M.; Farczadi, L.; Veres, M.; Azamfirei, L. Analytical Methods for Melatonin Quantification: Advances, Challenges, and Clinical Applications. Pharmaceuticals 2026, 19, 439. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Albrethsen, J.; Andreasen, J.K.; Anton, J.; Sennels, H.P.; Jørgensen, H.L.; Hannibal, J.; Hermann, D.; Wewer Albrechtsen, N.J. Measurements of plasma melatonin by rapid LC-MS/MS enables insight into diurnal variation in healthy humans. Scand. J. Clin. Lab Invest 2026, 86, 306–312. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Karel, P.; Schutten, E.; van Faassen, M.; Wanschers, H.; Brouwer, R.; Mulder, A.L.; Kema, I.P.; Reichman, L.J.; Krabbe, J.G. A comparison of two LC-MS/MS methods and one radioimmunoassay for the analysis of salivary melatonin. Ann. Clin. Biochem. 2021, 58, 387–388. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Shin, S.; Oh, H.; Park, H.R.; Joo, E.Y.; Lee, S.Y. A Sensitive and Specific Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Quantification of Salivary Melatonin and Cortisol: Development and Comparison With Immunoassays. Ann. Lab Med. 2021, 41, 108–113. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. van Faassen, M.; Peters, M.A.M.; Walenkamp, A.M.; de Vries, E.G.E.; Oosting, S.F.; Kema, I.P. Melatonin is not stored in platelets. Clin. Chim. Acta 2019, 498, 17–20. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  59. EMA. European Medicines Agency (EMA). Melatonin Neurim (Melatonin): EPAR—Public Assessment Report; EMEA/H/C/005603/0000; EMA/847216/2022; Committee for Medicinal Products for Human Use (CHMP): Amsterdam, The Netherlands, 2022; Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/melatonin-neurim (accessed on 28 August 2026).
  60. Dahlén, E.; Bergman Perland, E.; Maria Bergsten, E.; Arthurson, V.; Kimland, E. The use of melatonin continues to increase-rational prescribing and follow-up is important. Lakartidningen 2025, 122, 24073. [Google Scholar] [PubMed]
  61. Bliddal, M.; Kildegaard, H.; Rasmussen, L.; Ernst, M.; Jennum, P.J.; Mogensen, S.H.; Pottegård, A.; Wesselhoeft, R. Melatonin use among children, adolescents, and young adults: A Danish nationwide drug utilization study. Eur. Child Adolesc. Psychiatry 2023, 32, 2021–2029. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  62. Kimland, E.E.; Bardage, C.; Collin, J.; Järleborg, A.; Ljung, R.; Iliadou, A.N. Pediatric use of prescribed melatonin in Sweden 2006–2017: A register based study. Eur. Child Adolesc. Psychiatry 2021, 30, 1339–1350. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Tedroff, K.; von Euler, M.; Dahlén, E. Melatonin usage in children and young adults, a registry-based cohort study. Eur. J. Paediatr. Neurol. 2022, 39, 30–34. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Valtuille, Z.; Acquaviva, E.; Trebossen, V.; Ouldali, N.; Bourmaud, A.; Sclison, S.; Gomez, A.; Revet, A.; Peyre, H.; Delorme, R.; et al. Prescription Trends of Medications Used to Treat Sleep Disturbances in School-Aged Children: An Interrupted Time-Series Analysis in France, 2016–2023. J. Pediatr. 2025, 280, 114502. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Wan, M.; Begum, R.; Rashed, A.N. Trends, geographical variation and factors associated with melatonin prescribing in general practices in England: A practice-level analysis. Br. J. Clin. Pharmacol. 2022, 88, 2430–2436. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. European Parliament and Council of the European Union. Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. In Official Journal of the European Communities; European Parliament and Council of the European Union: Strasbourg, France, 2002; Volume L 31, pp. 1–24. [Google Scholar]
  67. EC. European Parliament and Council of the European Union. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. Off. J. Eur. Union L 2002, 183, 51–57. [Google Scholar]
  68. Schulze, H.; Conrads, B.; Saerbeck, U.; Breitweg-Lehmann, E. Produkte mit Mikronährstoffen: Arzneimittel oder Lebensmittel? Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2025, 68, 1219–1225. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  69. Vanhee, C.; Degrève, C.; Boschmans, N.; Naïmi, Y.; Canfyn, M.; Deconinck, E.; Willocx, M. Validated UHPLC Methods for Melatonin Quantification Reveal Regulatory Violations in EU Online Dietary Supplements Commerce. Molecules 2025, 30, 2647. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  70. Skrzelowski, M.; Brookhaus, A.; Shea, L.A.; Berlau, D.J. Melatonin Use in Pediatrics: Evaluating the Discrepancy in Evidence Based on Country and Regulations Regarding Production. J. Pediatr. Pharmacol. Ther. 2021, 26, 4–20. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  71. NIH. National Institutes of Health: Melatonin: What You Need To Know. 2021. Available online: https://www.nccih.nih.gov/health/melatonin-what-you-need-to-know (accessed on 8 September 2026).
  72. HC. Notice of Intent: Health Canada Is Changing The Prescription Drug List Qualifier Related to Pediatric Melatonin Use. 2026. Available online: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/qualifier-pediatric-melatonin-intent.html (accessed on 8 September 2026).
  73. EC. European Parliament and Council of the European Union. Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Off. J. Eur. Union L 2006, 404, 1–45. [Google Scholar]
  74. EC. European Parliament and Council of the European Union. Regulation (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation of health claims as provided for in Article 15 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council (1). Off. J. Eur. Union L 2008, 109, 11–17. [Google Scholar]
  75. EFSA. Health Claims. January 2026. Available online: https://www.efsa.europa.eu/en/topics/topic/health-claims (accessed on 8 September 2026).
  76. European Food Safety Authority (EFSA). Panel on Dietetic Products, Nutrition and Allergies: Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698, 1780, 4080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011, 9, 2241. [Google Scholar] [CrossRef] [Scilit]
  77. European Parliament and Council of the European Union. Commission Regulation (EU) No 432/2012 of 16 May 2012 Establishing a List of Permitted Health Claims Made on Foods, Other than Those Referring to the Reduction of Disease Risk and to Children’s Development and Health. Off. J. Eur. Union 2012, 136, 1–40. [Google Scholar]
  78. EFSA. EFSA Panel on Nutrition, Novel Foods and Food Allergens. General Scientific Guidance for Stakeholders on Health Claim Applications (Revision 1). EFSA J. 2021, 19, e06553. [Google Scholar] [CrossRef] [Scilit]
  79. Bendadani, C.; Bakhiya, N.; Breitweg-Lehmann, E.; Ehlers, A.; Hirsch-Ernst, K.I.; Liebscher, B.; Weißenborn, A. Food supplements and fortified foods: Benefits, risks and approaches to consumer protection. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2025, 68, 1226–1236. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  80. BfR. Melatoninhaltige Nahrungsergänzungsmittel: BfR weist auf mögliche Gesundheitsrisiken hin: Stellungnahme Nr. 042/2024 des BfR vom 17. September 2024. In BfR-Stellungnahmen; Bundesinstitut für Risikobewertung: Halem, Germany, 2024; Volume 2024. [Google Scholar]
  81. Vanhee, C.; Deconinck, E.; George, M.; Hansen, A.; Hackl, A.; Wollein, U.; El-Atma, O.; Beerbaum, N.; Aureli, F.; Borioni, A.; et al. The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. J. Xenobiot. 2025, 15, 88. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  82. European Directorate for the Quality of Medicines and HealthCare. Technical Guide for the Elaboration of Monographs on Medicinal Products Containing Chemically Defined Active Substances; EDQM: Strasbourg, France, 2020; Available online: https://www.edqm.eu/documents/52006/66555/Technical+Guide+for+the+elaboration+of+monographs+on+medicinal+products+containing+chemically+defined+active+substances+%282020%29.pdf/6950fa2b-a75c-3969-b561-fbc7afc74cd4 (accessed on 8 September 2026).
  83. Council of Europe. Chapter 2.9.40, Uniformity of Dosage Units. In European Pharmacopoeia, 11th ed.; Council of Europe: Strasbourg, France, 2022. [Google Scholar]
  84. Erland, L.A.; Saxena, P.K. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. J. Clin. Sleep Med. 2017, 13, 275–281. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  85. Freeman, D.I.; Lind, J.N.; Weidle, N.J.; Geller, A.I.; Stone, N.D.; Lovegrove, M.C. Notes from the Field: Emergency Department Visits for Unsupervised Pediatric Melatonin Ingestion-United States, 2019–2022. MMWR Morb. Mortal. Wkly. Rep. 2024, 73, 215–217. [Google Scholar] [CrossRef] [PubMed]
  86. Lelak, K.; Vohra, V.; Neuman, M.I.; Toce, M.S.; Sethuraman, U. Pediatric Melatonin Ingestions-United States, 2012-2021. MMWR Morb. Mortal. Wkly. Rep. 2022, 71, 725–729. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  87. Kuehn, B.M. Climbing Melatonin Use for Insomnia Raises Safety Concerns. JAMA 2022, 328, 605–607. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  88. Cohen, P.A.; Avula, B.; Wang, Y.-H.; Katragunta, K.; Khan, I. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA 2023, 329, 1401–1402. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  89. Pawar, R.S.; Coppin, J.P.; Khanna, S.; Parker, C.H. A Survey of Melatonin in Dietary Supplement Products Sold in the United States. Drug Test. Anal. 2025, 17, 1176–1185. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  90. Li, W.; Wertheimer, A. Narrative Review: The FDA’s Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events. Innov. Pharm. 2023, 14, iip.v14i1.4989. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  91. Jalil, B.; Heinrich, M. Pharmaceutical quality of herbal medicinal products and dietary supplements-a case study with oral solid formulations containing Lavandula species. Eur. J. Pharm. Sci. 2025, 208, 107042. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  92. Crawford, C.; Lindsey, A.T.; Avula, B.; Katragunta, K.; Khan, I.A.; Deuster, P.A. Label Accuracy and Quality of Select Weight-Loss Dietary Supplements Sold on or near US Military Bases. Nutrients 2024, 16, 4369. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  93. Hu, H.; Redan, B.; Celiz, M.D.; Pawar, R.; Yakes, B.J. Perspective on Gummy Dietary Supplements Manufacturing and Testing. J. Diet. Suppl. 2026, 1–12. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  94. Knopf, H. Selbstmedikation mit Vitaminen, Mineralstoffen und Nahrungsergänzungsmitteln in Deutschland. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2017, 60, 268–276. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  95. Hartstein, L.E.; Garrison, M.M.; Lewin, D.; Boergers, J.; Hiraki, B.K.; Harsh, J.R.; LeBourgeois, M.K. Factors contributing to U.S. parents’ decisions to administer melatonin to children. Sleep Med. 2024, 114, 49–54. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  96. Glass, A.; Attrill, C.; Magee, C.; Blunden, S. Factors associated with melatonin use in child sleep disturbance: A survey of Australian parents. Sleep Med. 2023, 107, 330–337. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  97. Owens, J.; Barnett, N.; Lucchini, M.; Berger, S. Melatonin use in infants and toddlers. Sleep Med. 2024, 120, 53–55. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  98. Lee, S.K.M.; Smith, L.; Tan, E.C.K.; Cairns, R.; Grunstein, R.; Cheung, J.M.Y. Melatonin use in children and adolescents: A scoping review of caregiver perspectives. Sleep Med. Rev. 2023, 70, 101808. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  99. Shenoy, P.; Etcheverry, A.; Ia, J.; Witmans, M.; Tablizo, M.A. Melatonin Use in Pediatrics: A Clinical Review on Indications, Multisystem Effects, and Toxicity. Children 2024, 11, 323. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  100. Matura, J.M.; Shea, L.A.; Bankes, V.A. Dietary supplements, cytochrome metabolism, and pharmacogenetic considerations. Ir. J. Med. Sci. 2022, 191, 2357–2365. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  101. Cowan, A.E.; Tooze, J.A.; Gahche, J.J.; Eicher-Miller, H.A.; Guenther, P.M.; Dwyer, J.T.; Potischman, N.; Bhadra, A.; Carroll, R.J.; Bailey, R.L. Trends in Overall and Micronutrient-Containing Dietary Supplement Use in US Adults and Children, NHANES 2007–2018. J. Nutr. 2023, 152, 2789–2801. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  102. Li, J.; Somers, V.K.; Xu, H.; Lopez-Jimenez, F.; Covassin, N. Trends in Use of Melatonin Supplements Among US Adults, 1999–2018. JAMA 2022, 327, 483–485. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  103. Stierman, B.; Mishra, S.; Gahche, J.J.; Potischman, N.; Hales, C.M. Dietary Supplement Use in Children and Adolescents Aged ≤19 Years-United States, 2017–2018. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1557–1562. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  104. Hartstein, L.E.; Garrison, M.M.; Lewin, D.; Boergers, J.; LeBourgeois, M.K. Characteristics of Melatonin Use Among US Children and Adolescents. JAMA Pediatr. 2024, 178, 91–93. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  105. Dollins, A.B.; Zhdanova, I.V.; Wurtman, R.J.; Lynch, H.J.; Deng, M.H. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc. Natl. Acad. Sci. USA 1994, 91, 1824–1828. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  106. Pires, M.L.; Benedito-Silva, A.A.; Pinto, L.; Souza, L.; Vismari, L.; Calil, H.M. Acute effects of low doses of melatonin on the sleep of young healthy subjects. J. Pineal Res. 2001, 31, 326–332. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  107. Yang, C.-M.; Spielman, A.J.; D’Ambrosio, P.; Serizaw, S.; Nunes, J.; Birnbaum, J. A Single Dose of Melatonin Prevents the Phase Delay Associated with a Delayed Weekend Sleep Pattern. Sleep 2001, 24, 272–281. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  108. Graw, P.; Werth, E.; Kräuchi, K.; Gutzwiller, F.; Cajochen, C.; Wirz-Justice, A. Early morning melatonin administration impairs psychomotor vigilance. Behav. Brain Res. 2001, 121, 167–172. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  109. Arangino, S.; Cagnacci, A.; Angiolucci, M.; Vacca, A.M.; Longu, G.; Volpe, A.; Melis, G.B. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am. J. Cardiol. 1999, 83, 1417–1419. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  110. Menczel Schrire, Z.; Phillips, C.L.; Chapman, J.L.; Duffy, S.L.; Wong, G.; D’Rozario, A.L.; Comas, M.; Raisin, I.; Saini, B.; Gordon, C.J.; et al. Safety of higher doses of melatonin in adults: A systematic review and meta-analysis. J. Pineal Res. 2022, 72, e12782. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  111. Ha, M.; Yoon, D.; Lee, C.Y.; Lee, M.; Kim, Y.W.; Lee, J.M.; Shin, J.Y. Investigating the safety profiles of exogenous melatonin and associated adverse events: A pharmacovigilance study using WHO-VigiBase. J. Pineal Res. 2024, 76, e12949. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  112. Dashti, H.S.; Vetter, C.; Lane, J.M.; Smith, M.C.; Wood, A.R.; Weedon, M.N.; Rutter, M.K.; Garaulet, M.; Scheer, F.; Saxena, R. Assessment of MTNR1B Type 2 Diabetes Genetic Risk Modification by Shift Work and Morningness-Eveningness Preference in the UK Biobank. Diabetes 2020, 69, 259–266. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  113. Zhu, H.; Zhao, Z.-J.; Liu, H.-Y.; Cai, J.; Lu, Q.-K.; Ji, L.-D.; Xu, J. The melatonin receptor 1B gene links circadian rhythms and type 2 diabetes mellitus: An evolutionary story. Ann. Med. 2023, 55, 1262–1286. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  114. Rubio-Sastre, P.; Scheer, F.A.; Gómez-Abellán, P.; Madrid, J.A.; Garaulet, M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep 2014, 37, 1715–1719. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  115. Li, Y.; Huang, T.; Redline, S.; Willett, W.C.; Manson, J.E.; Schernhammer, E.S.; Hu, F.B. Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: Insights from three prospective cohort studies. Lancet Diabetes Endocrinol. 2024, 12, 404–413. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  116. Hadi, S.; Hadi, V.; Mohammadzadeh, M.; Jahangirfard, B. Effects of melatonin supplementation on blood glycemic indices in adults: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Nutr. Metab. 2026, 23, 27. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  117. Qian, J.; Stefanovski, D.; Andersen, P.A.K.; Vujovic, N.; Kelly, L.; Lepson, J.; Nguyen, H.; Byrne, S.; Wang, W.; Mandrup-Poulsen, T.; et al. Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes Care 2026, 49, 1498–1506. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  118. Kripke, D.F.; Kline, L.E.; Shadan, F.F.; Dawson, A.; Poceta, J.S.; Elliott, J.A. Melatonin effects on luteinizing hormone in postmenopausal women: A pilot clinical trial NCT00288262. BMC Womens Health 2006, 6, 8. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  119. Bellipanni, G.; Bianchi, P.; Pierpaoli, W.; Bulian, D.; Ilyia, E. Effects of melatonin in perimenopausal and menopausal women: A randomized and placebo controlled study. Exp. Gerontol. 2001, 36, 297–310. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  120. Anderson, R.A.; Lincoln, G.A.; Wu, F.C. Melatonin potentiates testosterone-induced suppression of luteinizing hormone secretion in normal men. Hum. Reprod. 1993, 8, 1819–1822. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  121. Terzolo, M.; Revelli, A.; Guidetti, D.; Piovesan, A.; Cassoni, P.; Paccotti, P.; Angeli, A.; Massobrio, M. Evening administration of melatonin enhances the pulsatile secretion of prolactin but not of LH and TSH in normally cycling women. Clin. Endocrinol. 1993, 39, 185–191. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  122. Waldhauser, F.; Lieberman, H.R.; Lynch, H.J.; Waldhauser, M.; Herkner, K.; Frisch, H.; Vierhapper, H.; Waldhäusl, W.; Schemper, M.; Wurtman, R.J.; et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol. Neuroendocrinology 1987, 46, 125–130. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  123. Pawlikowski, M.; Kolomecka, M.; Wojtczak, A.; Karasek, M. Effects of six months melatonin treatment on sleep quality and serum concentrations of estradiol, cortisol, dehydroepiandrosterone sulfate, and somatomedin C in elderly women. Neuro Endocrinol. Lett. 2002, 23, 17–19. [Google Scholar] [PubMed]
  124. Nickelsen, T.; Demisch, L.; Demisch, K.; Radermacher, B.; Schöffling, K. Influence of subchronic intake of melatonin at various times of the day on fatigue and hormonal levels: A placebo-controlled, double-blind trial. J. Pineal Res. 1989, 6, 325–334. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  125. Voordouw, B.C.; Euser, R.; Verdonk, R.E.; Alberda, B.T.; de Jong, F.H.; Drogendijk, A.C.; Fauser, B.C.; Cohen, M. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J. Clin. Endocrinol. Metab. 1992, 74, 108–117. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  126. Saraiva, S.P.; D’Aurea, C.V.R.; Luz, C.S.S.; Amaral, F.G.; Cipolla-Neto, J.; Marqueze, E.C.; Moreno, C.R.C. Low-Dose Melatonin, Climacteric Symptoms and Sleep in Female Shift Workers: A Randomized Controlled Trial. J. Pineal Res. 2026, 78, e70140. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  127. Yi, M.; Wang, S.; Wu, T.; Zhang, X.; Jiang, L.; Fang, X. Effects of exogenous melatonin on sleep quality and menopausal symptoms in menopausal women: A systematic review and meta-analysis of randomized controlled trials. Menopause 2021, 28, 717–725. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  128. Ninomiya, T.; Iwatani, N.; Tomoda, A.; Miike, T. Effects of exogenous melatonin on pituitary hormones in humans. Clin. Physiol. 2001, 21, 292–299. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  129. Rajaratnam, S.M.; Dijk, D.J.; Middleton, B.; Stone, B.M.; Arendt, J. Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. J. Clin. Endocrinol. Metab. 2003, 88, 4303–4309. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  130. Seabra, M.L.; Bignotto, M.; Pinto, L.R., Jr.; Tufik, S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J. Pineal Res. 2000, 29, 193–200. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  131. Terzolo, M.; Piovesan, A.; Osella, G.; Torta, M.; Buniva, T.; Paccotti, P.; Wierdis, T.; Angeli, A. Exogenous melatonin enhances the TRH-induced prolactin release in normally cycling women: A sex-specific effect. Gynecol. Endocrinol. 1991, 5, 83–94. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  132. Terzolo, M.; Piovesan, A.; Puligheddu, B.; Torta, M.; Osella, G.; Paccotti, P.; Angeli, A. Effects of long-term, low-dose, time-specified melatonin administration on endocrine and cardiovascular variables in adult men. J. Pineal Res. 1990, 9, 113–124. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  133. Knutson, K.L.; Dixon, D.D.; Grandner, M.A.; Jackson, C.L.; Kline, C.E.; Maher, L.; Makarem, N.; Martino, T.A.; St-Onge, M.-P.; Johnson, D.A.; et al. Role of Circadian Health in Cardiometabolic Health and Disease Risk: A Scientific Statement From the American Heart Association. Circulation 2025, 152, e408–e419. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  134. Nnadi, E.; Masara, M.; Offor, R.; Unal, S.; Rebah, R.; Atere, M.; Nigussie, B.; Graham-Hill, S. Abstract 4371606: Effect of Long-term Melatonin Supplementation on Incidence of Heart Failure in Patients with Insomnia. Circulation 2025, 152, A4371606. [Google Scholar] [CrossRef] [Scilit]
  135. Khan, B.; Lima, B.B. Melatonin and cardiovascular risk: An NHANES reality check after recent heart failure concerns. Open Heart 2026, 13, e004108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  136. Ang, S.P.; Chia, J.E.; Thirupathy, U.; Laezzo, M.; Jaiswal, V.; Varon, J.; Halma, M.; Lee, E.; Davidson, G.; Iglesias, J. Melatonin Supplementation and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials. J. Clin. Med. 2026, 15, 3444. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  137. Gangar, J.; Sahota, P.; Thakkar, M. 0968 Melatonin Use and Heart Failure: A Retrospective Observational Study. Sleep 2026, 49, A431–A432. [Google Scholar] [CrossRef] [Scilit]
  138. European Medicines Agency. Circadin EPAR: Product Information. EMEA/H/C/000695; EMA: Amsterdam, The Netherlands, 2025; Available online: https://www.ema.europa.eu/en/documents/product-information/circadin-epar-product-information_en.pdf (accessed on 2 October 2026).
  139. Ursing, C.; Wikner, J.; Brismar, K.; Röjdmark, S. Caffeine raises the serum melatonin level in healthy subjects: An indication of melatonin metabolism by cytochrome P450(CYP)1A2. J. Endocrinol. Investig. 2003, 26, 403–406. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  140. Kroon, L.A. Drug interactions with smoking. Am. J. Health Syst. Pharm. 2007, 64, 1917–1921. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  141. Ursing, C.; von Bahr, C.; Brismar, K.; Röjdmark, S. Influence of cigarette smoking on melatonin levels in man. Eur. J. Clin. Pharmacol. 2005, 61, 197–201. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  142. Otmani, S.; Demazières, A.; Staner, C.; Jacob, N.; Nir, T.; Zisapel, N.; Staner, L. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum. Psychopharmacol. 2008, 23, 693–705. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  143. Suhner, A.; Schlagenhauf, P.; Höfer, I.; Johnson, R.; Tschopp, A.; Steffen, R. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviat. Space Environ. Med. 2001, 72, 638–646. [Google Scholar] [PubMed]
  144. Okatani, Y.; Okamoto, K.; Hayashi, K.; Wakatsuki, A.; Tamura, S.; Sagara, Y. Maternal-fetal transfer of melatonin in pregnant women near term. J. Pineal Res. 1998, 25, 129–134. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  145. Reppert, S.M.; Klein, D.C. Transport of maternal[3H]melatonin to suckling rats and the fate of [3H]melatonin in the neonatal rat. Endocrinology 1978, 102, 582–588. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  146. Schenker, S.; Yang, Y.; Perez, A.; Acuff, R.V.; Papas, A.M.; Henderson, G.; Lee, M.P. Antioxidant transport by the human placenta. Clin. Nutr. 1998, 17, 159–167. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  147. Zemdegs, I.Z.; McMillen, I.C.; Walker, D.W.; Thorburn, G.D.; Nowak, R. Diurnal rhythms in plasma melatonin concentrations in the fetal sheep and pregnant ewe during late gestation. Endocrinology 1988, 123, 284–289. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  148. Ejaz, H.; Figaro, J.K.; Woolner, A.M.F.; Thottakam, B.M.V.; Galley, H.F. Maternal Serum Melatonin Increases During Pregnancy and Falls Immediately After Delivery Implicating the Placenta as a Major Source of Melatonin. Front Endocrinol. 2020, 11, 623038. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  149. Häusler, S.; Lanzinger, E.; Sams, E.; Fazelnia, C.; Allmer, K.; Binder, C.; Reiter, R.J.; Felder, T.K. Melatonin in Human Breast Milk and Its Potential Role in Circadian Entrainment: A Nod towards Chrononutrition? Nutrients 2024, 16, 1422. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  150. Nakamura, Y.; Tamura, H.; Kashida, S.; Takayama, H.; Yamagata, Y.; Karube, A.; Sugino, N.; Kato, H. Changes of serum melatonin level and its relationship to feto-placental unit during pregnancy. J. Pineal Res. 2001, 30, 29–33. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  151. Joseph, T.T.; Schuch, V.; Hossack, D.J.; Chakraborty, R.; Johnson, E.L. Melatonin: The placental antioxidant and anti-inflammatory. Front Immunol. 2024, 15, 1339304. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  152. Vine, T.; Brown, G.M.; Frey, B.N. Melatonin use during pregnancy and lactation: A scoping review of human studies. Braz. J. Psychiatry 2022, 44, 342–348. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  153. Hobson, S.R.; Gurusinghe, S.; Lim, R.; Alers, N.O.; Miller, S.L.; Kingdom, J.C.; Wallace, E.M. Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia. J. Pineal Res. 2018, 65, e12508. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  154. Quach, D.; Mol, B.W.; Springer, J.; Tully, E.; Higgins, C.; Jones, M.; Hennes, D.; Pham, Y.; Swarnamani, K.; Palmer, K.; et al. A double-blind, randomized, placebo-controlled trial of melatonin as an adjuvant agent for induction of labor: The MILO trial. Acta Obstet. Gynecol. Scand. 2024, 103, 2442–2454. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  155. Oliveira, F.S.; Dieckman, K.; Mota, D.; Zenner, A.J.; Schleusner, M.A.; Cecilio, J.O.; Vieira, F.V.M. Melatonin in Human Milk: A Scoping Review. Biol. Res. Nurs. 2025, 27, 142–167. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  156. Paditz, E. Melatonin in infants—Physiology, pathophysiology and intervention options. Somnologie 2024, 28, 103–109. [Google Scholar] [CrossRef] [Scilit]
  157. Illnerová, H.; Buresová, M.; Presl, J. Melatonin rhythm in human milk. J. Clin. Endocrinol. Metab. 1993, 77, 838–841. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  158. Iavarone, S.; Massoud, M.; Di Felice, G.; Pulcinelli, F.; Rapini, N.; Luciani, M. Antiplatelet Effect of Melatonin through Breastfeeding: A Pediatric Case Report. Children 2023, 10, 1839. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  159. Bishop-Freeman, S.C.; Young, K.A.; Labay, L.M.; Beuhler, M.C.; Hudson, J.S. Melatonin Supplementation in Undetermined Pediatric Deaths. J. Anal. Toxicol. 2022, 46, 808–816. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  160. Labay, L.M.; Kraner, J.C.; Mock, A.R.; Sozio, T.J. The Importance of Melatonin Detection in Pediatric Deaths. Acad. Forensic Pathol. 2019, 9, 24–32. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  161. Eckerberg, B.; Lowden, A.; Nagai, R.; Akerstedt, T. Melatonin treatment effects on adolescent students’ sleep timing and sleepiness in a placebo-controlled crossover study. Chronobiol. Int. 2012, 29, 1239–1248. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  162. van Geijlswijk, I.M.; Korzilius, H.P.L.M.; Smits, M.G. The Use of Exogenous Melatonin in Delayed Sleep Phase Disorder: A Meta-analysis. Sleep 2010, 33, 1605–1614. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  163. van Geijlswijk, I.M.; Mol, R.H.; Egberts, T.C.; Smits, M.G. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. Psychopharmacology 2011, 216, 111–120. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  164. van Geijlswijk, I.M.; van der Heijden, K.B.; Egberts, A.C.; Korzilius, H.P.; Smits, M.G. Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: An RCT. Psychopharmacology 2010, 212, 379–391. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  165. Zwart, T.C.; Smits, M.G.; Egberts, T.C.G.; Rademaker, C.M.A.; van Geijlswijk, I.M. Long-Term Melatonin Therapy for Adolescents and Young Adults with Chronic Sleep Onset Insomnia and Late Melatonin Onset: Evaluation of Sleep Quality, Chronotype, and Lifestyle Factors Compared to Age-Related Randomly Selected Population Cohorts. Healthcare 2018, 6, 23. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  166. Bakalov, D.V.; Pavlina, A.G.; Tafradjiiska-Hadjiolova, R.K. Differences between paediatric and adult suspected neuropsychiatric adverse drug reactions of Melatonin reported to the European Medicines Agency. Biotechnol. Biotechnol. Equip. 2021, 35, 805–811. [Google Scholar] [CrossRef] [Scilit]
  167. Waldhauser, F.; Weiszenbacher, G.; Frisch, H.; Zeitlhuber, U.; Waldhauser, M.; Wurtman, R.J. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1984, 1, 362–365. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  168. Boafo, A.; Greenham, S.; Alenezi, S.; Robillard, R.; Pajer, K.; Tavakoli, P.; De Koninck, J. Could long-term administration of melatonin to prepubertal children affect timing of puberty? A clinician’s perspective. Nat. Sci. Sleep 2019, 11, 1–10. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  169. Sadikova, E.; Szmulewicz, A.; Rakesh, D.; Tiemeier, H. The effect of melatonin supplement use on pubertal timing: Target trial emulation in the Adolescent Brain Cognitive Development study. Am. J. Epidemiol. 2025, kwaf062. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  170. Händel, M.N.; Andersen, H.K.; Ussing, A.; Virring, A.; Jennum, P.; Debes, N.M.; Laursen, T.; Baandrup, L.; Gade, C.; Dettmann, J.; et al. The short-term and long-term adverse effects of melatonin treatment in children and adolescents: A systematic review and GRADE assessment. EClinicalMedicine 2023, 61, 102083. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  171. Givler, D.; Givler, A.; Luther, P.M.; Wenger, D.M.; Ahmadzadeh, S.; Shekoohi, S.; Edinoff, A.N.; Dorius, B.K.; Jean Baptiste, C.; Cornett, E.M.; et al. Chronic Administration of Melatonin: Physiological and Clinical Considerations. Neurol. Int. 2023, 15, 518–533. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  172. Edemann-Callesen, H.; Andersen, H.K.; Ussing, A.; Virring, A.; Jennum, P.; Debes, N.M.; Laursen, T.; Baandrup, L.; Gade, C.; Dettmann, J.; et al. Use of melatonin in children and adolescents with idiopathic chronic insomnia: A systematic review, meta-analysis, and clinical recommendation. EClinicalMedicine 2023, 61, 102048. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  173. Kracht, C.L.; Bolamperti, G.; Breeden, R.; Crocker, M.; Christifano, D.N.; Gibler, R.C.; Gyllenborg, G.; Johnson, P.; Lovell, J.; Mathews, L.; et al. Melatonin Use in Young Children: A Systematic Review. JAMA Netw. Open 2026, 9, e2551958. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  174. Owens, J. Melatonin use in the pediatric population: An evolving global concern. World J. Pediatr. 2025, 21, 1081–1089. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  175. Owens, J.; Simakajornboon, N.; Kotagal, S.; Gringras, P. Melatonin use in managing insomnia in typically developing (TD) children: A technical report. Sleep Med. 2025, 128, 89–94. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.